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Blood coagulation and thrombosis 
Blood coagulation helps to protect the integrity of the vascular system 
following tissue injury. The process of blood clotting and then subsequent 
dissolution of clot, is termed hemostasis. Under physiological 
circumstances, hemostasis is a tightly regulated process that prevents 
excessive blood loss upon vascular injury.1 Upon vascular damage, a 
hemostatic clot is formed at the site of injury, which is accomplished by a 
very rapid activation of pre-existing proteins. The coagulation cascade is 
activated, vessels constrict, platelets aggregate and form a platelet plug. 
Simultaneously, a series of enzymatic reactions occurs which converts 
fibrinogen to fibrin and ultimately results in the formation of a cross-linked 
fibrin-clot which stabilizes platelet thrombi, thus, repairing the vascular 
injury.2-4 Anticoagulant factors limit activation of coagulation to the site of 
injury1 and fibrinolysis gradually dissolves the fibrin clump at the site of the 
lesion, and thus results in a normalization of the blood circulation at this 
level (Figure 1).5 The equilibrium between procoagulant, anticoagulant and 
fibrinolytic factors is tightly regulated to provide hemostasis at the site of the 
injury.6 However, imbalance between procoagulant, anticoagulant and 
fibrinolytic factors can lead to conditions such as hypocoagulable or 
hypercoagulable states, which can subsequently result in bleeding or 
thrombosis, respectively.7  
Thrombosis is unwanted thrombus formation in the vessels, obstructing the 
blood flow through the circulatory system. Thrombosis can occur both in 
arteries and veins which is associated with arterial (myocardial infarction 
and stroke) and venous disorders (venous thrombosis and pulmonary 
embolism), respectively.8 This dissertation centers on the transcriptional 
regulation of coagulation factor genes to understand the mechanism(s) by 
which (risk) factors induce a hypercoagulable state and increase the risk for 





Figure 1: Schematic overview of coagulation cascade. Upon vascular injury, normalized 
blood circulation is guaranteed by controlled procoagulant, anticoagulant (red lines) and 
fibrinolysis pathways. (Licenced by GNU Free Documentation Licence, version 1.2) Adapted 
from: http://commons.wikimedia.org/wiki/File:Coagulation_full.svg  
 
Venous thrombosis and venous thrombosis risk factors 
The incidence of venous thrombosis is 2-3 per 1000 inhabitants per year, 
and has a steep age gradient e.g. an annual incidence of 1 per 100 
individuals in the elderly may be attained.9 As early as 1856, Virchow 
published the famous “Virchow’s triad”, which postulated that thrombosis is 
caused by at least one of the following factors: alterations in blood flow 
(stasis), alterations in the composition of the blood and damage to the 
vascular wall.10 Virchow’s broad classification remains valid in the 21st 
century. Traditionally, it has been shown that the risks of venous 
thrombosis are mainly related to either changes in blood flow (stasis) or the 
composition of the blood (hypercoagulability), whereas changes in the 




classifications for risk factors of venous thrombosis is based on genetic and 
acquired risk factors that result in stasis and/or a hypercoagulable state.9;11  
Inherited genetic risk factors are often related to abnormal blood 
composition resulting in hypercoagulability. Deficiencies of anticoagulant 
factors, such as antithrombin, protein C and protein S, and their association 
with clinical venous thrombosis were described in the 20th century.12-15 
Homozygous deficiencies of anticoagulant factors are extremely rare and 
lead to purpura fulminans (disseminated intravascular coagulation) in 
newborns, which is life-threatening.16;17 In contrast, the prevalence of 
heterozygous deficiencies is more common in the general population at 
about 1 in 500-2000 individuals. Heterozygosity increases the risk for 
venous thrombosis about 10-fold.18-20  
Not only the relatively rare deficiencies of natural anticoagulants are of 
importance, but also more common gain-of-function mutations of 
procoagulant factors are associated with increased risk of thrombosis. 
Factor V Leiden and prothrombin-20210A mutations are quite common (2% 
- 5% in Caucasians populations) and increase the risk of venous 
thrombosis 2- to 7-fold.21-23 Another genetic risk factor for venous 
thrombosis is non-O blood group, which indirectly increases FVIII levels 
and thrombosis risk.24-26 Moreover, several common polymorphisms were 
identified in or near the procoagulant factor XI (FXI) gene that lead to 
higher levels of FXI which are associated with thrombosis.27;28 Mutation in 
fibrinogen gamma gene increased the risk of venous thrombosis 2.4-fold.29 
Besides genetic risk factors, there are several acquired risk factors that 
increase the risk of venous thrombosis, such as prolonged immobilization, 
surgery, obesity, pregnancy, malignancies, increased thyroid hormone 
levels and use of female hormone (oral contraceptives or hormone 
replacement therapy).11;30-37  
A number of these acquired risk factors are associated with a 




hormones and obesity, coincide with changes in coagulation, probably by 
modulating gene transcription in the liver.38-42 Since, the liver is the main 
organ for the production of plasma coagulation factors, a prothrombotic 
state may occur when altered transcription of the coagulation genes in the 
liver leads to an imbalance in the ratio of pro- and anti-coagulant proteins in 
the plasma. However, the mechanisms by which the aforementioned 
conditions modulate hepatic transcription of coagulation genes have not 
been completely elucidated. We hypothesized that hepatic transcription 
factors can become dysregulated, and that this dysregulation underlies the 
hypercoagulable state observed for a number of acquired conditions 
associated with an increased risk for venous thrombosis.  
 
Transcriptional control of blood coagulation genes 
Transcription of genes is mediated by transcription factors and their co-
regulatory proteins. Transcription factors bind at or near the gene promoter 
in a sequence-specific manner to regulate gene expression, either as 
enhancer or as repressor. Under physiological conditions, transcription of 
genes encoding coagulation factors is regulated to produce sufficient 
amounts of coagulation factors in order to achieve hemostatic equilibrium 
and a clot-free blood circulation. 
Plasma coagulation factors are mainly produced in the liver. A number of 
ChIP (chromatin immunoprecipitation) and in vitro functional studies 
provided evidence that constitutive expression of plasma coagulation 
factors is guaranteed by a panel of (liver-specific) transcription factors. For 
example, mutagenesis studies showed that hepatocyte nuclear factor 
(HNF)1α, HNF3β, and specificity protein Sp1/Sp3, are important in the 
regulation of prothrombin expression.43 Functional promoter activity assays 
in the human liver-derived cell line HepG2 provided evidence of binding 
regions of HNF1α and HNF4α to the promoter of protein S.44 Furthermore, 




major factors controlling FIX and protein C expression respectively.45-47 
Other in vitro studies reported the transcriptional regulation of coagulation 
factor X by GATA-4 and Sp1.48 Amongst others, hepatic transcription 
factors HNF4α and CCAAT/enhancer-binding protein α (C/EBPα) are of 
particular interest. These factors are not only abundantly expressed in liver 
and are important for liver development and function in general, but they 
also suspected to contribute directly to the transcription of a number of 
coagulation genes. In addition, liganded estrogen and thyroid hormones 
receptors may interact with these factors43;49-55 which suggests that these 
transcription factors potentially may play a role as an intermediate for 
increasing the risk of thrombosis associated with these hormones. Thus, 
several liver transcription factors have the capability to regulate coagulation 
gene expression. Nevertheless, the exact contribution of these transcription 
factors in regulating coagulation gene transcription in vivo is limited. Further 
(in vivo) studies are required to understand the exact contribution of liver-
specific transcription factors in the development of a hypercoagulable state 
and consequent increased risk for developing VT.  
A second mechanism that is used to regulate coagulation genes is 
mediated via transcription factors that play a relatively minor role in 
constitutive expression, but inducible through environmental or metabolic 
pathways. For instance, obesity is associated with hyperinsulinemia, a pro-
inflammatory state, and increased transcription of the factor VIII, fibrinogen-
gamma and PAI-1 genes that results from increased activity of the 
transcription factor nuclear factor kappaB (NF-κB).56;57 Upon inflammation, 
tissue factor gene expression is induced in monocytes via activator protein 
1 (AP-1), NF-κB and Sp1.58 Thus, obesity and its related inflammation 
contribute to modulation of above mentioned coagulation gene expression 
in a multistep process resulting in a hypercoagulable state. Mouse and 




affected upon nutritionally induced obesity,42 but whether the observed 
effects can be explained by aforementioned mechanisms, is not known yet.   
Nuclear hormone receptors are able to bind to hormone response elements 
in the promoter regions of target genes, and thereby are able to modulate 
gene transcription. In vivo studies have shown that use of exogenous 
estrogens (component of oral contraceptive pills or hormone replacement 
therapy which is acquired risk factors of venous thrombosis) modulates 
hepatic expression of several genes via estrogen receptor α.38 In vitro 
functional and in vivo ChIP-on-chip studies have identified estrogen 
response elements in promoter regions of murine genes encoding 
fibrinogen, FII, FVII, FX, FXI, FXIII, α2-antiplasmin, heparin cofactor II, 
protein S, protein Z and plasminogen.39;59 Studies of our own group 
indicated that estrogens are also able to modulate mouse hepatic gene 
expression of a large number of coagulation genes (encoding fibrinogen-γ, 
FII, FV, FVII, FX, FXI, FXII, antithrombin, protein C, protein Z, protein Z 
inhibitor and heparin cofactor II) via estrogen receptor α (ERα).38 Thus, 
estrogen hormone modulates transcription of a number of coagulation 
genes via ERα, and altered transcription coincides with altered plasma 
activity levels of coagulation proteins. 
Besides transcription factors, coregulatory proteins may have an impact on 
constitutive coagulation gene transcription. Transcription factors typically 
regulate gene expression by binding to DNA and recruiting multiple 
regulatory proteins (co-activators, co-repressors and pioneer factors) and 
RNA polymerase II to the site of transcription initiation. Co-regulators and 
pioneer factors alter the transactivation properties of (nuclear hormone) 
transcription factors by promoting several events, such as chromatin 
remodeling, recruitment of the pre-initiation complex and movement of RNA 
polymerase and thereby make the associated DNA more or less accessible 
for transcription. A coregulator group of steroid receptor co-activators 




and SRC-3 (NCOA3) are reported to interact with ERα and to alter ERα 
transcriptional properties.60;61 These coregulators possess histone 
acetyltransferase activity and lead to relaxing of the chromatin, which then 
allows the basal transcription machinery and other factors to access the 
promoter of the target genes.62 Amongst others, FOXA1 (Hepatocyte 
Nuclear Factor 3α), a pioneer factor that has recently been extensively 
studied in prostrate, breast and non-breast cancer cells (osteosarcoma cell 
line), is able to maintain euchromatic conditions (loosely coiled and 
transcriptionally active DNA) at specific cis-regulatory elements.63;64 Several 
reports have described that FOXA1 participates in several gene regulatory 
events with nuclear hormone receptors including ERα.65-67 Co-regulators 
may not affect the basal transcriptional activity on its own, as they modulate 
gene expression together with transcription factors, although co-regulators 
may contain an autonomous activation function. Thus, nuclear hormone 
receptors together with their coregulatory proteins may form intermediates 
leading to changes in coagulation gene transcription, subsequent changes 
in the plasma coagulation profile, thereby contributing to a prothrombotic 
condition. 
From the above it follows that there are several levels at which coagulation 
gene expression can be modulated. The exact contribution of transcription 
factors, co-regulatory and intermediate proteins in regulating the 
transcription of the coagulation genes is largely unknown. Studying the 
mechanisms underlying hepatic coagulation gene transcription in more 
detail may increase our understanding why a thrombotic risk condition 
coincides with abnormal coagulation profiles. Experimental model systems 
in which transcriptional regulation of coagulation is conserved are required 
to obtain such insights. 
 
Model systems to study transcriptional control of coagulation genes 




Different model systems to study the control of coagulation genes are 
available, ranging from in vitro and ex vivo to in vivo (mouse) models. Most 
of the coagulation factors are produced by the liver (hepatocytes), and 
several hepatocytic cell lines are available such as HepG2 (human liver-
derived cell line), Hepa 1-6 and Hepa-1c1c7 (both mouse liver-derived cell 
lines). Many in vitro studies aimed at understanding the transcriptional 
control of coagulation genes have been performed in the HepG2 cell line 
via functional promoter activity assays and mutagenesis studies.43;44;48 A 
disadvantage of hepatocytic cell lines is that they poorly express 
coagulation factors. We have also observed that both mouse hepatocyte 
cell lines (Hepa 1-6 and Hepa1c1c7) poorly express coagulation genes as 
compared to mouse liver, which limits the use of hepatocyte cell lines for 
the study of coagulation gene transcription. Primary (mouse) hepatocyte 
cultures form an ex vivo model system that expresses coagulation factors 
may be useful to study coagulation control. The disadvantage of primary 
hepatocyte cultures is that expression of coagulation factors only remains 
stable for a limited period after isolation; thereafter expression of a number 
of genes including coagulation genes start decreasing. Reduction in gene 
expression may be due to the experimental procedures like hepatocyte 
isolation and artificial culturing conditions. Therefore, primary hepatocyte 
cultures also are of limited usefulness. Shortcomings of in vitro and ex vivo 
cultures can be circumvented by using animal models. These may provide 
a model system with physiological expression and regulation of hepatic 
coagulation genes closest to the human situation, including all necessary 
known and unknown, but essential factors, relevant to coagulation gene 
transcriptional regulation.   
In vivo 
As compared to in vitro and ex vivo cultures, in vivo models allow studying 




mouse is the most used mammalian model organism in biomedical 
research. About 85% of genes are conserved between humans and mice 
and the animal's small size facilitates large scale, high throughput studies 
making this animal model a cost-efficient.68 Furthermore, liver-specific gene 
regulation is to a large extent conserved between humans and mice.53 
Regarding coagulation, murine coagulation factors and their functions in the 
hemostatic system are comparable to their human counterparts.69;70 Hence, 
mice may form a suitable in vivo model organism to study the regulation of 
hepatic coagulation genes and how thrombotic risk conditions coincide with 
hypercoagulable state.  
Although the use of mice in hemostasis research may be advantageous, 
there are also limitations; they do not develop spontaneous thrombosis 
thereby hampering the impact of altered regulation on clinical end points, 
i.e. thrombosis. However, several genetic and experimental thrombosis 
models are available which showed a thrombotic phenotype and used in 
thrombosis studies.71;72 Hence, results from mice models offer the 
possibility to study mechanistic insight into biological processes and allow 
for example to study gene function in the in vivo situation. Therefore, the 
mouse was used as a model system for studies described in this 
dissertation.  
Gene function in in vivo models 
Gene knockout 
A powerful method to analyze gene function and gene regulation is by 
making ‘a knockout’ mouse of your (regulatory) gene of interest. Gene 
inactivation is obtained via homologous recombination in mouse ES cells73-
76. With this method an essential part of the gene of interest is completely 
removed or destroyed. Although this approach provides the possibility to 
study gene function in vivo, there are some limitations. For example, 




become activated when a gene is missing, and this complicates the 
interpretation of the contribution of the gene under study. Moreover, 
products of many genes may be essential for normal function and 
embryonic development, and inactivating such genes might induce gross 
morphological or physiological abnormalities or may be fetal. As an 
example, conventional knockout mice of two important hepatic transcription 
factors, HNF4α and C/EBPα, were embryonic or neonatal lethal, 
respectively.77;78 This can be explained by the fact that these transcription 
factors regulate genes that are also required for embryonic 
development.54;55;79  
Not only deletion of transcription factors but also deletion of coagulation 
genes like antithrombin, protein C and protein S appeared embryonic lethal 
due to severe coagulopathy.80-83  
Conditional gene knockout using the Cre-loxP system84-87 allows to 
knockout genes of interest in specific tissues, and at a particular time point, 
circumventing early lethality. Cre recombinase, is a site specific integrase 
that catalyzes recombination between recognition (loxP) sites that 
encompass the target gene. Promoter choice is important in controlling the 
site and timing of Cre recombinase expression. To generate conditional 
knockout mice, a mouse line containing modified Cre recombinase under 
the control of an inducible tissue specific and/or time-dependent promoter 
(which stayed non-functional until inducing agent is produced or 
administrated)  is crossed with a mouse line in which the target gene is 
flanked by loxP sites (flox).86 The resulting offspring containing both Cre 
transgene and (loxP) flanked target gene, Cre recombinase will excise the 
targeted gene segment, through promoter dependent Cre-mediated 
recombination in specific tissue.86 For example, HNF4α and C/EBPα liver-
specific conditional knockout mice were generated by using albumin-Cre 
transgenic mice to direct recombination in hepatocytes.84;85 The efficiency 




birth recombination is about 40% and completes by the age of six weeks. 
Therefore, HNF4α and C/EBPα liver-specific conditional knockout mice are 
viable and have proven to be a very useful tool to study gene function in 
development, several metabolic pathways, and to some extent their role in 
coagulation gene transcription.52;55;84;88  
Despite the many advantages of conditional knockout animals, even these 
remain imperfect. For example, HNF4α liver-specific conditional knockout 
mouse model, (based on albumin-Cre promoter) requires four to six weeks 
for significant and complete deletion of HNF4α in mouse liver, thereby 
possibly missing the primary role of this gene because unwanted 
compensatory mechanisms are activated in the meantime. Moreover, 
HNF4α liver-specific conditional knockout mouse liver had not only visibly 
gray, molted appearance but also pathological lesions were observed in 
liver.84 Thus, prolonged deletion of HNF4α may change the liver physiology 
and alter expression of other transcription factors, thereby leading to 
misinterpretation of a direct role of gene in mouse. Alternative to albumin-
Cre, fast and rapid hepatic deletion of (part of) the target gene can be 
achieved by means of adenovirus-mediated hepatic delivery of the required 
Cre-recombinase or by inducible liver-specific gene disruption based on the 
Mx1-Cre system.89-91 The Mx1-Cre system utilizes the inducible Mx1 
promoter to control the expression of the Cre recombinase transgene and 
can be transiently activated to high levels of transcription by introducing 
interferon and thus delete the target gene rapidly. However, experimental 
factors are concomitant with acute inflammation or a burst of interferon 
application89-91 which may affect the organ physiology and may lead to 
possible misinterpretation of the direct role of specific targeted gene in 
gene regulation. Furthermore, even with the emergence of high-throughput 
gene knockout methods (conventional and conditional), the production of 




strategies may be useful not only to improve time- and labor-efficiency but 
also to achieve a fast and acute in vivo inactivation of the gene of interest. 
  
Gene knockdown – RNA interference (RNAi) 
For a number of research questions, RNA interference (RNAi) may serve 
as an alternative to the (conditional) knockout approach. RNAi is a natural 
process that mammalian cells use to reduce the expression of specific 
gene(s) at the post-transcriptional level and this mechanism was 
discovered by Fire, Mello and colleagues in 1998.92 RNAi is a process by 
which gene expression is reduced/regulated by endogenous double 
stranded RNA (dsRNA) in which one strand is partially complementary to a 
section of a gene’s mRNA.93-95 The dsRNA precursor is cleaved in the 
cytoplasm by an enzyme of the Dicer family into effector microRNAs 
(miRNAs), which are single-stranded 21-23 nucleotide long RNA 
molecules.96-99 Next, miRNAs are assembled into an RNA-induced silencing 
complex (RISC).99 Finally, the antisense miRNA strand guides the RISCs to 
the complementary mRNA, where they cleave and destroy the cognate 
RNA and inhibit protein synthesis.100 It has been reported that miRNAs 
incorporated into RISC are recycled, thus down regulating gene expression 
with only a small amount of miRNA.101  
Methods of mediating the RNAi effect for experimental purposes, involve 
synthetic small interfering RNA (siRNA) and short hairpin RNA (shRNA). 
shRNA can be produced inside the cell from a DNA construct, it is first 
processed by Dicer to small interfering RNA and continues along the RNAi 
pathway via RISC to silence the gene. siRNA and shRNA are exogenous, 
synthetic and double-stranded RNA, whereas miRNA on the other hand is 
an endogenous, natural and single-stranded RNA, often derived from the 
intronic region of a gene. However, processing and behavior of both miRNA 
and siRNA is same. siRNAs (manufactured by chemical synthesis) and 




mRNA. siRNA can be used to knock down gene expression selectively 
without any genomic manipulations in vitro and in vivo.102 The gene 
silencing via siRNA in a sequence specific manner has caused it to attract 
much attention for application in biosciences and medicine.102-105 Although 
living up to their apparent promise there are some challenges like siRNA 
delivery, knockdown efficiency and off-target effects, which are addressed 
later in this chapter.  
 
RNAi as an alternative approach to study gene function 
Expression of a gene(s) can be modulated with RNAi in vivo to study gene 
function. RNAi can be achieved by means of shRNA or siRNA. shRNA 
contains a hairpin like stem-loop that resembles intermediates of the 
endogenous miRNA pathway.106;107 shRNA can be incorporated into an 
adenoviral vector, and upon infection with these vectors in vivo efficient 
knockdown of gene expression can be achieved in mouse liver.108 
Knockdown of a target gene may persist for weeks, as the viral shRNA can 
be continuously synthesized by the host cell. However, viral vectors 
containing shRNA raised concerns about hepatotoxicity in mice.109;110 
Additionally, shRNA may interfere with gene regulation mediated by 
endogenous miRNAs.  
RNAi can also be achieved by means of 20-22 nucleotide long double 
stranded synthetic siRNA that specifically mediates degradation of mRNAs 
transcribed from a certain gene.111 Use of synthetic siRNA has advantages 
over shRNA; first, they are easy to synthesize and different chemical 
modifications can be introduced with ease to increase the stability in 
biological systems. Second, siRNAs are less likely to interfere with gene 
regulation mediated by endogenous miRNAs, because siRNA enters the 
RNAi pathway later.112 However, siRNAs exhibit low membrane 
permeability, because of a poor hydrophobicity and they are sensitive to 




in cells, particularly when systemic administration is necessary. Therefore, 
suitable delivery systems are required for in vivo applications. Only hepatic 
siRNA delivery systems with or without vehicles will be briefly described 
below, as the aim of this dissertation is to study the transcriptional control of 
(blood) coagulation factors solely at the level of the (mouse) liver.  
 
Targeting siRNA to the liver 
The biggest challenge of using siRNA as a tool to study gene function in 
vivo is the difficulty of siRNA delivery (e.g. delivery to the liver).113;114 In 
order to overcome delivery barriers, several strategies with non-viral 
systems have been developed, from naked siRNA (without any vehicle) to 
formulation of siRNA with lipids or synthetic polymers to deliver siRNA to 
the liver.115;116 Each delivery system comes with its own in vivo application 
(system) with varying margins of efficiency.  
  
Naked siRNA delivery without vehicle 
Several research groups used hydrodynamic delivery of naked siRNA to 
achieve gene silencing in the mouse liver. Two parameters are critical for 
hydrodynamic delivery, injection volume (9% body weight by volume) and 
speed of intravenous tail vein injection.117-119 This method of siRNA delivery 
to mouse hepatocytes results in enlargement of the liver fenestra and the 
generation of transient pores in the plasma membrane of hepatocytes. 
Hydrodynamic delivery enables siRNA to get into the cells in highly 
vascularized organs, such as the liver, and to efficiently knockdown 
endogenous gene expression in mice.120 However, in contrast to what has 
been reported, in our hands the typical gene knockdown achieved by this 
method is only 20-40%121 [and own unpublished observations]. 
Furthermore, hydrodynamic injection requires a high level of technical skill 
and causes transient liver damage, characterized by cell swelling, some 




 siRNA delivery with vehicles 
A variety of vehicles have been documented to deliver siRNA, including 
peptide-mediated delivery and complexed glycan encapsulated siRNA 
particles, liposomes (lipid bilayer vesicle) formulations e.g. lipoplexes 
(complexes of cationic lipids and nucleic acids), or lipid nanoparticles 
(LNPs) typically containing ionizable amino acids.116;123;124 However, 
liposome-based vehicles can cause inflammatory toxicity through activation 
of the innate immune response.125 LNPs are advanced siRNA delivery 
systems. These are colloidal carriers that consist of a lipid matrix which is 
composed of physiological components, thereby overcoming the innate 
immune responses. Alternatively, siRNAs can be linked to ligands of cell 
surface receptors for endocytosis to target the delivery of the siRNAs to 
cells that bear a specific receptor. For example, complexing siRNA with 
polyethyleneimine-hyaluronic acid (PEI-HA) induces efficient gene silencing 
in the tissues expressing hyaluronic acid receptors (e.g. liver).126  These 
strategies deliver siRNAs via receptor-mediated endocytosis, although the 
trafficking of siRNAs into and within cells has not been well studied. 
Another delivery strategy is to complex siRNA with lipidoids. Lipidoids 
belong to the most mature class of lipid-based systemic delivery vehicles 
and are synthesized by conjugate addition of an acrylate or acrylamide to 
primary or secondary amines of lipids.127 These lipidoids resulted in 
effective hepatic siRNA delivery and gene knockdown in vivo.127;128 Three 
years ago, a user friendly lipidoid-like, liposome-based siRNA delivery tool 
became available through Life Technologies under the name of 
Invivofectamine® 2.0 which delivers siRNA to mouse liver. Invivofectamine 
may contain physiological components as Life Technologies claimed 
minimal toxicity using this delivery vehicle without releasing the full 
specifications. Single intravenous tail vein injection of siRNA complexed 
using Invivofectamine efficiently delivers siRNA to the liver and can result in 




siRNA per kilogram body weight was claimed to provide an efficient 
knockdown of the hepatic target gene. Moreover, Invivofectamine as a 
delivery vehicle offers the opportunity to knockdown multiple hepatic target 
genes (up to four) simultaneously.129  
 
Scope of the dissertation 
The scope of this dissertation was to study the mechanisms by which 
hepatic coagulation gene transcription is regulated, in order to increase our 
understanding of how thrombotic risks conditions coincide with 
hypercoagulable state. We investigated the contribution of transcription 
factors, co-regulatory and intermediate proteins (HNF4α, C/EBPα and 
FOXA1) in hepatic transcriptional regulation of coagulation factors. In the 
present dissertation, we employed synthetic siRNAs in mice to further detail 
our knowledge on hepatic genes that are part of (anti)coagulation genes 
and/or are suspected to contribute in regulation of coagulation factor 
production. 
  
Outline of the dissertation 
We proposed that synthetic siRNA could serve as a tool to study the exact 
contribution of hepatic transcription factors, co-regulatory and intermediate 
proteins in regulating the transcription of coagulation genes. In chapter 2, 
we successfully used synthetic siRNAs to target HNF4α in mouse primary 
hepatocytes, determined the impact on mouse coagulation gene 
transcription, and compared the findings to those observed in livers of mice 
conditionally lacking HNF4α. Synthetic siRNA appeared a relatively simple 
and fast approach as compared to a (conditional) knockout approach to 
study gene function, which encouraged us to use synthetic siRNAs in an in 
vivo setting.  
Next, we set out to develop a siRNA-based approach to efficiently 




knockdown of hepatic gene expression of our first target genes, i.e. HNF4α 
and C/EBPα, was achieved with synthetic siRNAs complexed with 
Invivofectamine 2.0® (chapter 3). We demonstrated the direct role of these 
two important hepatic transcription factors in vivo in controlling gene 
regulation of blood coagulation factors. We also compared the hepatic gene 
expression of HNF4α knockdown and liver-specific conditional HNF4α 
knockout mice to explore the direct targets of HNF4α and validation of 
usefulness of siRNA technology. These studies showed that HNF4α and 
C/EBPα are important transcription factor in controlling hepatic gene 
transcription of a number of coagulation genes. Moreover, these studies 
revealed that our approach is suitable as an alternative to knockout 
approach when studying hepatic mouse genes. 
siRNA-mediated knockdown of genes may not only be useful to study 
hepatic transcription factors but it can also be a useful method to study 
intermediate co-regulatory proteins such as FOXA1 in mouse liver. FOXA1 
is a major determinant of the estrogen response in breast and non-breast 
cancer cells. The study described in chapter 4 was aimed to investigate 
the role of FOXA1 as an intermediate factor in estrogen hormone response 
in regulating (more specifically coagulation) gene transcription in mouse 
liver. siRNA-mediated knockdown of FOXA1 modulated estrogen-induced 
ERα chromatin interaction in mouse liver. 
Next, the siRNA approach was used to explore the function of 
anticoagulant genes for which the knockout appeared embryonic lethal. In 
chapter 5 we described the successful hepatic knockdown of antithrombin 
and protein C (alone or in combination). This shed new light on the function 
of these anticoagulants and provided a novel mouse model featuring a 
spontaneous (venous) thrombotic phenotype. 
In chapter 6, we investigated the regulation of coagulation factor 11 (F11) 




F11 gene cluster was analyzed under several metabolic conditions, and 
included studies on the role of HNF4α by using our in vivo siRNA approach. 
In chapter 7, all the generated experimental data are discussed in a 
broader context and future perspectives are described. In the last and final 
chapter, chapter 8, the main findings of studies described in this 
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Hepatocyte Nuclear Factor 4α (HNF4α) is a transcription factor belonging to 
the steroid/thyroid hormone nuclear receptor superfamily that is expressed 
at high levels in the liver, and is suspected to be critical for the synthesis of 
a large number of hepatic coagulation factors. In vitro gene promoter 
studies identified functional HNF4α binding sites near the genes encoding 
human procoagulant factors (F) II (F2), VII (F7), VIII (F8), IX (F9), X (F10), 
XI (F11), XII (F12),1-7 and anticoagulant factors protein S (PROS1), protein 
Z (PROZ) and antithrombin III (SERPINC1).8-10 The in vivo importance of 
HNF4α in regulating hepatic transcription of procoagulant genes was 
established by examining hepatic mRNA levels from liver-specific HNF4α-
null mice.11 Northern blot analysis demonstrated the impact of Hnf4α 
deletion on expression of F5, F9, F11, F12 and F13b, whereas no effect 
was observed on expression of F2, F7, F8 and F10.11 Although in vitro 
studies suggest that HNF4α may also be critical in regulating transcription 
of hepatic factors involved in anticoagulation and fibrinolysis,8-10 here its 
importance in vivo remains presently unknown. Because the HNF4α-null 
mouse studies demonstrated that in vitro promoter analysis studies are not 
a reliable indicator of a crucial transcriptional role of HNF4α,11 we decided 
to study its involvement in the expression of anticoagulation and fibrinolysis 
genes in vivo as well. 
The role of HNF4α was studied using liver mRNA samples from 45-days-
old male liver specific HNF4α-null mice (HNF4α-floxed/floxed with albumin-
Cre; KO) and control mice (HNF4α-floxed/floxed without albumin-Cre; 
FLOX),11 by real time RT-PCR on the relevant genes (for methods see)12). 
We first demonstrated that livers of KO mice were devoid of Hnf4α 
transcript levels and Hnf4α protein levels (Figure 1A and 1C, respectively), 
we subsequently confirmed strong reductions in procoagulant F5 and F12 




 and fibrinolysis genes, male KO mice displayed markedly reduced 
transcript levels of hepatic protein C inhibitor (Serpina5, -100%), protein Z 
(Proz, -97%), and α2-antiplasmin (Serpinf2, -77%) (Figure1A). Moderate 
reductions were observed for Protein Z inhibitor (Serpina10, -34%) (Figure 
1A). Protein C (Proc, -28%), protein S (Pros1, -15%), plasminogen (Plg, -
5%) and antithrombin (Serpinc1, +13%) transcript levels were not 
significantly affected by the hepatic loss of Hnf4α, whereas hepatic mRNA 
levels of Heparin Cofactor II (Serpind1, +75%) were significantly increased 
in KO as compared to FLOX mice (Figure 1A). Hepatic tissue-type 
plasminogen activator (Plat), α2-macroglobulin (A2m) and plasminogen 
activator inhibitor-1 (Serpine1) mRNA levels were too low to detect. 
Differences in hepatic anticoagulation and fibrinolysis gene transcript levels 
upon liver specific Hnf4α deletion in age-matched littermate female KO and 
FLOX mice were essentially the same as observed for the males (data not 
shown). 
We also investigated whether the observed HNF4α-mediated changes in 
anticoagulation and fibrinolysis gene transcript levels in vivo would replicate 
in normal mouse primary hepatocytes following acute Hnf4α siRNA-
mediated knockdown - thus excluding delayed and/or indirect effects of 
Hnf4α deletion on transcription of coagulation genes. Hepatocytes were 
isolated from male C57Black/6J mice through retrograde collagenase 
perfusion13 and cells were cultured in collagen S-coated 6-well plates in 
complete DMEM. Twenty four hours after isolation, cells (at ~85% 
confluency) were transfected with Hnf4α-specific (siHnf4α) or control siRNA 
(siScrambled). Forty-eight hours after siRNA transfection, Hnf4α transcript 
levels in siHnf4α transfected hepatocytes were decreased by 80% as 
compared to siScrambled transfected cells (Figure 1B), which was 
paralleled by a comparable reduction in Hnf4α protein levels (Figure 1D). 
Reduction in hepatocyte Hnf4α expression coincided with significant 
reductions in transcript levels of the anticoagulant genes Serpina5 (-45%), 





Figure 1: Anticoagulation and fibrinolysis gene transcript levels in livers of HNF4α-
null mice and cultured mouse primary hepatocytes transfected with Hnf4α-specific 
siRNA. 
Anticoagulation and fibrinolysis gene transcript levels in (A) liver tissue from 45-day-old male 
liver specific Hnf4α-null (KO, ■) and control (FLOX, □) mice, and (B) in mouse primary 
hepatocytes 48 hours after transfection with 100nM Hnf4α-specific siRNA (■) or control 
siRNA siScrambled (□) (Dharmacon Lafayette, CO, USA J-065463-07, target sequence 
GCG AAC UCC UUC UGG AUG A or D001810-01, siScrambled sequence UGG UUU ACA 
UGU CGA CUA AUU respectively) using the Dharmafect Duo transfection reagent® 
(Dharmacon, T-2010-03). Quantitative real-time PCR was performed as described (12). 
Gene-specific primers used were described before (12) with the exception of those for 




TCC ATC ATG GA). β-actin was used as internal control for quantification and 
normalization. The _Ct values of the individual samples were related to the mean _Ct of the 
reference group (FLOX or siScrambled). On the x-axis the coagulation and fibrinolysis 
genes are ranked according to the magnitude of effects observed in vivo. Data are 
expressed as mean ± standard error of the mean. For the in vivo studies, 8 animals per 
group were used. For the in vitro studies, a representative of 3 individual experiments is 
shown, each performed in triplicate. Hnf4α protein levels in KO and FLOX mice (C) and 
mouse primary hepatocytes which were transfected with siHnf4α or siScrambled (D) siRNA 
as determined by Western blot analysis on liver or cell homogenates (15μg total protein 
lysate) using anti-Hnf4α antibody (C-19, sc- 6556, Santa Cruz biotech., Santa Cruz, USA). 
ß-actin was used as protein loading control. 
In vivo and in vitro data were statistically analysed using Mann-Witney U-test and unpaired t-
test, respectively. P-values < 0.05 were regarded as statistically significant. *P<0.05, 
**P<0.01, ***P<0.001 
 
Proz (-71%), Serpina10 (-31%), Pros1 (-35%), the fibrinolysis related gene 
Serpinf2 (-75%) and control procoagulant genes F5 (-30%), F12 (-57%) 
(Figure 1B). Proc, Serpinc1, and Plg transcript levels were not significantly 
affected by siHnf4α , while mRNA levels of Serpind1 significantly increased 
(+46%) in siHnf4α transfected cells as compared to siScrambled cells 
(Figure 1B). Thus, the HNF4α-mediated changes in anticoagulation and 
fibrinolysis gene transcript levels in livers of 45-days-old HNF4α-null mice 
were largely reproduced in wild type mouse primary hepatocytes rapidly 
following siRNA-mediated Hnf4α knockdown. 
In conclusion, our in vivo data, point to an important role for HNF4α in 
regulating hepatic transcription of mouse Serpina5, Proz, Serpinf2, 
Serpina10 and Serpind1. Our in vitro data support these findings and 
suggest that this control is direct and does not involve intermediates. Thus, 
hepatic HNF4α is critical for regulation of a number of hepatic procoagulant 
genes11 as well as anticoagulant and fibrinolysis genes, showing HNF4α 
importance in blood coagulation homeostasis. 
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Hepatocyte nuclear factor 4α (HNF4α) and CCAAT/enhancer-binding 
protein α (C/EBPα) are important for the transcriptional control of 
coagulation factors. To determine in vivo the direct role of HNF4α and 
C/EBPα in control of genes encoding coagulation factors, a synthetic small 
interfering (si)RNA approach was used that enabled strong reduction of 
mouse hepatic HNF4α and C/EBPα under conditions that minimized target-
related secondary effects.  For both HNF4α and C/EBPα, intravenous 
injection of specific synthetic siRNAs (siHNF4α and siC/EBPα) resulted in 
more than 75% reduction in their liver transcript and protein levels 2 days 
post-injection. For siHNF4α, this coincided with marked and significantly 
reduced transcript levels of the coagulation genes Hrg, Proz, Serpina5, 
F11, F12, F13b, Serpinf2, F5, and F9 (in order of magnitude of effect) as 
compared to levels in control siRNA injected animals. Significant decreases 
in HNF4α target gene mRNA levels were also observed at 5 days post-
siRNA injection, despite a limited level of HNF4α knockdown at this time 
point. Compared to HNF4α, C/EBPα knockdown had a modest impact on 
genes encoding coagulation factors. A strong reduction in C/EBPα 
transcript and protein levels resulted in significantly affected transcript 
levels of the control genes Pck1 and Fasn and a modest downregulation for 
coagulation genes Fba, Fbg and F5. F5 and F11 were the sole coagulation 
genes that were significantly affected upon prolonged (5 day) C/EBPα 
knockdown. We conclude that in the mouse, HNF4α has a direct and 
essential regulatory role for multiple hepatic coagulation genes, while a role 
for C/EBPα is more restricted. In addition, this study demonstrates that 
synthetic siRNA provides a simple and fast means for determining liver 





Hepatocyte nuclear factor 4α (HNF4α) and CCAAT/enhancer-binding 
protein α (C/EBPα) are two distinct transcription factors that are of key 
importance in controlling many genes specifically expressed in the liver and 
associated with a number of critical metabolic pathways.1-3 In addition, both 
transcription factors are claimed to be critical for control of the hepatic 
genes encoding proteins in the coagulation pathway. For HNF4α, first 
evidence came from in vitro gene promoter studies for human coagulation 
genes. Functional HNF4α binding sites were identified near the genes 
encoding factor (F) II (F2), VII (F7), VIII (F8), IX (F9), X (F10), XI (F11), XII 
(F12), protein S (PROS1), protein Z (PROZ) and antithrombin III 
(SERPINC1).4-13  
The in vivo importance of HNF4α in regulating hepatic transcription of 
coagulation genes described in studies using hepatocyte-specific HNF4α 
knockout mice.14;15 Hnf4a disruption affected expression of factor (F) F5, 
F9, F11, F12, F13b, protein C inhibitor (Serpina5), protein Z (Proz), α2-
antiplasmin (Serpinf2), protein Z inhibitor (Serpina10), and heparin Cofactor 
II (Serpind1), whereas no effects were observed for F2, F7, F8, F10, 
protein S (Pros1) and antithrombin (Serpinc1).14;15 For C/EBPα, studies on 
the relevance to coagulation are limited. A recent CHIPseq study 
determined the genome-wide occupancy of C/EBPα in the livers of human, 
mouse, dog, opossum, and chicken. Fibrinogen A (FGA) and F2 were 
identified among 32 genes located near 35 C/EBPα binding events that 
were conserved among these five vertebrates.16 In the mouse genome, Fga 
and F2, C/EBPα binding sites were 45 and 64 bp from the transcription 
start site, respectively. However, it should be emphasized that binding does 
not necessarily correlate with functional activity in controlling gene 
transcription. Furthermore, carriers of hemophilia B Leiden have a causal 
mutation in a C/EBPα binding site in F9 promoter,17 and in line, liver-
specific C/EBPα-null mice display reduced hepatic expression of F9.17;18 











































































Finally, in vitro studies demonstrated requirement of C/EBPα for F8 
expression, but this involved nonhepatic inflamed cells.19 Whether other 
coagulation genes other than FGA, F2, F9 and F8 are regulated by C/EBPα 
is unknown.  
The study of the in vivo roles of HNF4α and C/EBPα in control of gene 
transcription in liver employed a conditional gene knockout approach 
because conventional gene knockouts for HNF4α and C/EBPα were 
embryonic lethal.20;21 In general, a conditional gene knockout approach 
does not allow a rapid significant deletion of the gene of interest in vivo 
without challenging liver physiology; fast adenovirus-mediated hepatic 
delivery of the required Cre- recombinase does allow rapid hepatic 
disruption of 'floxed' alleles but is concomitant with adenovirus-related 
acute hepatic inflammation.22;23 Similarly, inducible liver-specific gene 
disruption based on the MX1-Cre transgene requires a burst of circulating 
interferon to evoke the necessary activation of MX1-Cre.24 Meaningful 
studies of the role of hepatic transcription factors can therefore only start 
after weaning of the adenovirus or interferon effects. At that time, 
transcription factor deletion may already have induced (secondary) 
changes in liver physiology and compensatory changes in expression of 
other hepatic transcription factors. It may lead to a possible 
misinterpretation of the direct role of a given transcription factor in gene 
regulation. Hence, the current observations regarding the role of HNF4α 
and C/EBPα in regulating coagulation gene transcription obtained in adult 
mice lacking HNF4α and C/EBPα from birth on (Cre recombinase under 
control of the albumin promoter),25 following Cre supplied by means of 
adenovirus26 or the MX1-Cre transgene27 may be in part secondary to 
changes in liver physiology and changes in expression of other hepatic 
transcription factors. This may, explain the unexpected transcriptional 
increase of numerous hepatically expressed genes including the 




targets F2, F7, F8, F10, Pros1 and Serpinc1 in livers from mice lacking 
HNF4α from birth.14;15 
Recently, lipid-based reagents became available that allow efficient delivery 
of synthetic small interfering (si) RNAs to livers of adult mice following 
systemic injection.28 Thus, transient knockdown of target gene expression 
can be achieved rapidly (within two days post siRNA delivery) and does not 
involve changes in liver physiology as a result of harsh methodology. In the 
present study, we used this in vivo siRNA approach to rapidly reduce 
HNF4α and C/EBPα expression in mouse livers and to determine the 
impact of these two distinct transcription factors on hepatic coagulation 
gene transcription. 
 
MATERIAL AND METHODS 
siRNA screening and validation 
Pre-designed siRNAs for mouse HNF4α and C/EBPα mRNAs were 
purchased from Ambion Applied Biosystems, Carlsbad, California, USA 
(Ambion Silencer® Pre-designed for HNF4α; catalogue numbers 67633 
(#1), 67634 (#2) and 67635 (#3) with sense sequences GGC AGA UGA 
UCG AAC AGA UUU, CCA AUG UCA UUG UUG CUA AUU, and AGA 
GGU CCA UGG UGU UUA AUU, respectively and for mouse C/EBPα; 
catalogue numbers 63853 (#1), 63854 (#2), 63855 (#3) with sense 
sequences GCA AAA AUG UGC CUU GAU AUU, AAA GCU GAG UUG 
UGA GUU AUU, and ACU CAA AAC UCG CUC CUU UUU, respectively). 
Ambion’s siNEG (catalogue number 4404020) was used as control siRNA. 
This negative control siRNA was selected using a modified blast to account 
for short sequence length and demonstrated to exclude significant 
homology to any known gene targets in RefSeq and MirBase (more 
detailed documentation on this negative control siRNA is available on the 
manufacturer’s website).29 Hepatocytes from female C57Black6/J mice 
(Charles River, Maastricht, The Netherlands) were isolated through 











































































retrograde collagenase perfusion and cultured in collagen-coated dishes 
exactly as previously described.30 Twenty four hours after isolation 106 cells 
were transfected with the siRNA (final concentration 0.3, 3 or 30 nM) using 
the Dharmafect Duo transfection reagent® (Dharmacon, T-2010-03) 
according to the manufacturer’s protocol. Twenty-four hours after 
transfection, levels of HNF4α and C/EBPα mRNAs were determined by 
quantitative real-time PCR (see below). Sequences from siRNAs yielding 
maximal reduction of transcript levels at a siRNA concentration of 3 nM 
were considered for use in in vivo studies. 
 
Gene knockdown in mouse liver 
Control siNEG, siHNF4α and siC/EBPα (Ambion In-Vivo-Ready for 
catalogue numbers 4404020, 67633 and 63855, respectively) were 
complexed with Invivofectamine® 2.0 Reagent (Invitrogen, Life 
technologies Corporation, USA) exactly according to the manufacturer’s 
protocol. Subsequently, female C57Black/6J mice (weighing 17–19 gram) 
were intravenously injected via the tail vein with 200µl complexed siRNA at 
a dose of approximately 7 mg of siRNA per kg body weight (in total 54 
animals, 18 animals per siRNA). At two and five days post siRNA injection, 
animals (9 mice per siRNA for each time point) were anesthetized by a 
subcutaneous injection with a mixture of ketamine (100 mg/kg), xylazine 
(12.5 mg/kg) and atropine (125 μg/kg) after which the abdomen was 
opened by a midline incision and a blood sample on sodium citrate (final 
concentration 0.32%) was drawn from the inferior caval vein. Plasma was 
obtained by centrifugation and stored at -80°C until use. Liver was isolated 
and weighed, and liver left lobule was snap-frozen for mRNA and protein 
analyses and stored at -80°C until use. All mice were housed under a 12-h 
light/dark cycle, with standard chow diet and drinking water provided ad 
libitum. All experimental procedures were approved by the animal welfare 




For HNF4α, as a reference, liver materials from 45-day old female HNF4α-
null mice with a liver-specific deletion of exons 4 and 5 of the Hnf4a gene 
(HNF4α-floxed/floxed with albumin-Cre; KO) or control mice (HNF4α-
floxed/floxed without albumin-Cre; FLOX)25 were used. 
 
RNA isolation and real-time RT-PCR 
Liver samples (20-30 mg) were homogenized in RNAzol (Tel-Test) and 
RNA isolation and cDNA synthesis was performed as previously 
described.31 Gene-specific quantitative real-time PCR (QPCR) primers for 
Pck1, Fasn, Scd1, Lgp and Gys2 have been described previously:32 all 
other gene specific QPCR primers were designed with the Primer Express 
software (Applied Biosystems). QPCR primer sequences are presented in 
Table 1. QPCR was performed on the ABI Prism 7900 HT Fast Real-Time 
PCR System from Applied Biosystems and data were analysed using the 
accompanying Sequence Detection System software. The comparative 
threshold cycle method with β-actin as internal control was used for 
quantification and normalization. siNEG-injected animals were set as a 
reference and the ΔCt values of the individual samples were related to the 
mean ΔCt of the reference group. 
 
Immunoblotting 
Frozen liver material (10-20 mg) was grounded, liver protein (15 µg) was 
denatured, separated on 8-10% Novex® Tri-Glycine gels, and 
immunoblotted using a goat polyclonal IgG against human HNF4α (sc-
6556, Santa Cruz Biotechnology) or rabbit polyclonal against rat C/EBPα 
(sc61, Santa Cruz Biotechnology). ß-actin was detected using rabbit 
polyclonal against human ß-actin (Ab8227, Abcam) and served as protein 
loading control. The antibodies are reactive to mouse HNF4α, C/EBPα 
(both p42 and p30 unit) and ß-actin, respectively. Bound IgG was detected 
using horseradish peroxidase-labeled anti-goat (sc-2020, Santa Cruz) or 











































































anti-rabbit (172-1019, Bio Rad) IgG followed by enhanced 
chemiluminescence system (Amersham Pharmacia Biotech) to detect 
peroxidase activity. 
 
Table 1: QPCR primer sequences 
Gene  Forward primer (5’- 3’) Reverse primer (5’- 3’) 
Actb AGGTCATCACTATTGGCAACGA CCAAGAAGGAAGGCTGGAAAA 
Apoc2 AAGATGACTCGGGCAGCCT CAGAGGTCCAGTAACTTAAGAGGGA 
Apoa4 CAGCTGACCCCATACATCCAG TCATCGAGGTGTGCAGGTTG 
Cd36 GTTCTTCCAGCCAATGCCTTT ATGTCTAGCACACCATAAGATGTACAGTT 
Cebpa ATAGACATCAGCGCCTACATCGA GTCGGCTGTGCTGGAAGAG 
Cebpb CGGGACTGACGCAACACA CCGCAGGAACATCTTTAAGTGATTA 
Cyp4v3 CTCTCCGAGTTTTCCCATCTGT TTGTAACCGCCCACTTCACA 
F2 GGACGCTGAGAAGGGTATCG CCCCACACAGCAGCTCTTG 
F5 CATGGAAACCTTACCGACAGAAA CATGTGCCCCTTGGTATTGC 
F7 CGTCTGCTTCTGCCTCTTAGA ATTTGCACAGATCAGCTGCTCAT 
F9 GCAAAACCGGGTCAAATCC ACCTCCACAGAATGCCTCAATT 
F10 GTGGCCGGGAATGCAA AACCCTTCATTGTCTTCGTTAATGA 
F11 GAAGGATACGTGCAAGGGAGATT CAAGTGCCAGACCCCATTGT 
F12 GGGCTTCTCCTCCATCACCTA GCAACTGTTGGTTTTGCTTTCC 
F13a1 GATGTCCTGGCCAAACAAAG GGCAGCACCTCGGACCTT 
F13b GACACTGCCCCCTGAGTGTGTTGAAA AACAACCACACCGTTTGCTATG 
Fasn CCCTTGATGAAGAGGGATCA ACTCCACAGGTGGGAACAAG 
Fga TTCTGCTCTGATGATGACTGGAA GGCTTCGTCAATCAACCCTTT 
Fgg TGCTGCCTGCTTTTACTGTTCTC TCTAGGATGCAACAGTTATCTCTGGTA 
Gys2 GACACTGAGCAGGGCTTTTC GGGCCTGGGATACTTAAAGC 
Hnf4a AGAGGTTCTGTCCCAGCAGATC CGTCTGTGATGTTGGCAATC 
Hrg AAAACGGATAATGGTGACTTTGC TCCCCTCCTCTCGCTCTTATAA 
Lgp CCAGAGTGCTCTACCCCAAT CCACAAAGTACTCCTGTTTCAGC 
Pck1 CTGGCACCTCAGTGAAGACA TCGATGCCTTCCCAGTAAAC 
Plg  TGACATTGCCCTGCTGGAAAC CAGACAAGCTGGAATGACTTTATCC 




Pros1 GGTGGCATCCCAGATATTTCC CACTTCCATGCAGCCACTGT 
Proz GCAGCCAGAGTCAGCCTAGCT CACGCCGGCACAGAAGTC 
Scarb1 GCCAGGAGAAATGCTTTTTGTT GGCCTGAATGGCCTCCTTA 
Scd1 AGCTGGTGATGTTCCAGAGG GTGGGCAGGATGAAGCAC 
Serpina5 TCTGGCATTACTGACCATACCAA GACTCTTCAACCTCCATCATGGA 
Serpina10 TGGCCCTGGAGGACTACTTG CCATTTTCCTGGTTTTCATATTCTG 
Serpinc1 TGGGCCTCATTGATCTCTTCA CCTGCCTCCAGCAACGAT 
Serpind1 GAATGGCAATATGTCAGGCATCT CACTGTGATGGTACTTTGGTGCTT 
Serpinf2 TTCTCCTCAACGCCATCCA GGTGAGGCTCGGGTCAAAC 
  
Plasma analyses 
Plasma alanine aminotransferase (ALT), aspartate aminotransferase 
(AST), alkaline phosphatase (ALP) and bilirubin (total and conjugated) 
levels were determined using routine clinical chemistry assays. Global 
coagulability of the plasma was determined by measuring the prothrombin 
time (PT, Simple Simon PT system, Zafena), and the activated partial 
thromboplastin time (APTT) by using the STA Neoplastin Plus reagent 
(Roche) on the STart 4 analyzer (Diagnostica Stago). Plasma F5 activity 
was analyzed by using chromogenic substrate conversion33 and activity 
levels of factor (F) F11 and F12 were measured with APTT-based assays.31 
Plasma fibrinogen antigen levels were assessed with a commercial murine 
ELISA kit from Affinity Biologicals. In plasma assays of individual 
coagulation factors, pooled normal mouse plasma was used to generate 
standard curves and the control siNEG-injected group was set as a 
reference (100%).  
 
Statistical analyses 
Data were analysed with the GraphPad Instat software. Statistical 
differences between control siNEG and siHNF4α or siC/EBPα groups were 
evaluated using a Mann-Whitney Rank sum test (animal studies) or 











































































Student’s t-test (hepatocyte studies). A P-value of <0.05 was considered to 
be statistically significant.  
 
RESULTS 
siRNA screening and validation 
To select an effective siRNA, mouse primary hepatocytes were transfected 
with three different predesigned synthetic siRNAs for HNF4α, and C/EBPα 
mRNAs. For HNF4α, all three siRNAs were highly and equally effective with 
over 95% reduction of Hnf4a transcript levels at a final concentration of 30 
nM (Figure 1A). siRNA duplex #3 had the highest level of knockdown of 
Hnf4a transcript levels at the 3 nM concentration and was selected for use 
in in vivo experiments. For C/EBPα, all three siRNAs tested were highly 
effective, albeit that the levels of reduction (~80%, Figure 1B) were 
somewhat lower as compared to the siRNAs for HNF4α. For C/EBPα 
siRNA duplex #1 was selected, being the most effective at 3 nM. The 
siHNF4α #3, siC/EBPα #1 and the siNEG were subjected to large-scale 
preparation in the lipid-based in vivo transfection reagent optimized for 
hepatic delivery, and injected intravenously into C57Black/6J female mice. 
Two days after injection, siHNF4α and siC/EBPα produced a more than 
75% reduction in liver Hnf4a and Cebpa transcript levels (Figure 2A and 
2B, respectively), as well as strongly reduced liver HNF4α and C/EBPα 
protein levels (Figure 2C). For siC/EBPα this strong level of knockdown of 
liver C/EBPα mRNA and protein persisted for at least five days (Figure 2B 
and 2D). For siHNF4α, HNF4α mRNA and protein levels remained reduced 
at five days, but, as quantified for the transcript, only at a mean level of 
36% (Figure 2A and 2D). This relatively quick return to normal HNF4α 
levels for siHNF4α was also observed in a second independent experiment 
and could not be overcome by a repeat intravenous siHNF4α injection (7 






Figure 1. Screening and validation of siRNAs in mouse primary hepatocytes.  
Screening of siRNA in mouse primary hepatocytes 24 hours after transfection with 0.3, 3 
and 30nM of three Hnf4a-specific (#1-3, panel A), three Cebpa -specific siRNAs (#1-3, panel 
B) or a control siRNA (siNEG, panel A and B, open bars). Hnf4a and Cebpa transcript levels 
were determined by quantitative real-time PCR. β-actin was used as internal control for 
quantification and normalization. The ΔCt values of the individual samples were related to 
the mean ΔCt of the reference group (siNEG). On the x-axis siRNA concentrations are 
indicated. Data are expressed as mean with error bars representing the difference between 
2 POWER of upper and lower range of the mean ΔΔCt (difference 2^ΔΔCt+SEM and 
2^ΔΔCt-SEM). Individual experiments were performed in triplicate. Data were statistically 
analyzed using the Student’s t-test. P-values < 0.05 were regarded as statistically 
significant. *P<0.05, **P<0.01, ***P<0.001 
 
During the 5-day observation period siHNF4α and siC/EBPα did not affect 
mouse body weight and liver weight as compared to siNEG injected 
animals or uninjected controls. Gross pathological analysis revealed no 
abnormalities. Plasma bilirubin, ALT, AST and ALP in siNEG injected 
animals were comparable to those observed for uninjected controls (Table 
2) as expected.28 As compared to the siNEG injected controls, at two days 
post siRNA injection, ALP levels were significantly increased by siHNF4α, 
and at 2 days significantly reduced by siC/EBPα.  At 2 and 5 days, plasma 
bilirubin, AST, ALT levels in siHNF4α and siC/EBPα were below the limits 
of detection and comparable to siNEG injected animals. 
 
 













































































Figure 2. Knockdown of HNF4α and C/EBPα in mouse liver. 
The selected siHNF4α-specific siRNA #3 (67635), siC/EBPα-specific siRNA #1 (63853) and 
a control siNEG were subjected to large-scale preparation in the lipid-based in vivo 
transfection reagent optimized for hepatic delivery and intravenously injected in C57Black/6J 
mice (7 mg siRNA per kg mouse, injection volume 200 µl, 18 animals per siRNA). At two 
and five days post siRNA injection, mice (n=9 per siRNA for both time points) were 
sacrificed and livers were subjected to HNF4α (panel A) or C/EBPα (panel B) transcript 
analysis by QPCR. β-actin was used as internal control for quantification and normalization. 
The ΔCt values of the individual samples were related to the mean ΔCt of the reference 
group (siNEG). Data are expressed as mean with error bars representing the difference 
between 2 POWER of upper and lower range of the mean ΔΔCt (see figure 1 legends). Data 
were statistically analysed using Mann Whitney Rank Sum test. P-values < 0.05 were 
regarded as statistically significant. ***P<0.001. In addition, immunoblotting for HNF4α and 
C/EBPα was performed for liver homogenates that were prepared for three randomly 
selected mice per siRNA for both two days (panel C) and five days post injection (panel D). 




Changes in transcription of control genes following liver HNF4α and 
C/EBPα knockdown  
In livers of 6-wk-old liver-specific HNF4α deficient animals25 apolipoprotein 
C2 (Apoc2), apolipoprotein A4 (Apoa4), and  cytochrome P450 family 
member 4v3 (Cyp4v3) are among the genes that are highly expressed in 
the liver and are strongly down-regulated by prolonged HNF4α ablation, 
whereas in these mice scavenger receptor B1 (Scarb1) and CD36 (Cd36) 
are among the genes that are strongly upregulated25;34 (Figure 3B). 
The upregulation is suspected to be secondary and may result of prolonged 
hepatic HNF4α ablation. In livers of mice two days post siHNF4α injection, 
like in livers of liver-specific HNF4α deficient mice, strongly reduced Apoc2, 
Apoa4 and Cyp4v3 transcript levels were observed (Figure 4A). Also at five 
days, Apoc2, Apoa4, and Cyp4v3 remained significantly reduced in 
siHNF4α compared to the siNEG injected animals, despite the limited level 
of HNF4α knockdown at this time point (Figure 4C and 2A).  Scarb1 and 
Cd36 transcript levels were not affected by siHNF4α injection at two or five 
days (Figure 4A and 4C). Mice in which hepatic C/EBPα has been targeted 
by recombinant adenovirus encoding siRNA against C/EBPα mRNA 
demonstrated a role in (fasted) liver glucose and fat metabolism by 
affecting amongst others transcription of phosphoenolpyruvate 
carboxykinase (Pck1), glycogen synthase (Gys2), fatty acid synthase 
(Fasn), stearoyl-CoA-desaturase 1 (Scd1) and liver glycogen phophatase 
(Lgp).32 As demonstrated in Figure 4B, two days post siC/EBPα injection, 
the livers of (non-fasted) mice displayed significant changes in transcript 
levels of Pck1 and Fasn, Scd1 displayed a 40% non-significant decrease, 
whereas Gys2 and Lgp were unaffected as compared to siNEG injected 
animals. As in C/EBPα knockouts35, siC/EBPα injection resulted in a 
significant increase in transcript levels of Cebpb (+73%, Figure 5) which is 
considered a compensatory response to C/EBPα knockdown.35 Cebpb, 








































Table 2: Plasma analysis of siHNF4α and siC/EPBα injected mice 
Data are represented as mean ± SEM with the group injected with negative siRNA set as a reference. *P<0.05 and **P<0.01 versus mice 
injected with control siNEG. Prothrombin time (PT), activated partial thromboplastin time (aPTT), Factor activity (F11), Factor 12 activity 
(F12), Fibrinogen antigen (Fbg) and circulating liver enzymes alanine transaminase (ALT), aspartate aminotransferase (AST), alkaline 
phosfatase (ALP) and plasma total bilirubin (Tbil). N.D. = not determined. Values for uninjected control mice: bilirubin 8.3 ± 0.2 µmol/L, 
ALT < 20 U/L, AST 28 ± 3 U/L, ALP 96 ± 6 U/L 
 2 days post siRNA injection 5 days post siRNA injection 
 siNEG siHNF4α siC/EPBα siNEG siHNF4α siC/EPBα 
PT (sec) 11.4 ± 0.1 11.4 ± 0.2 11.6 ± 0.1 12.2 ± 0.1 11.8 ± 0.1* 12.5 ± 0.1* 
aPTT (sec) 28.2 ± 0.6 28.6 ± 0.8 27.8 ± 0.4 31.0 ± 0.4 31.9 ± 0.7 30.6 ± 0.6 
F5 (%) 100 ± 7 80 ± 11 90 ± 5 100 ± 7 126 ± 6 83 ± 5 
F11 (%) 100 ± 6 80 ± 4* N.D. 100 ± 5 90 ± 8 N.D. 
F12 (%) 100 ± 2 100 ± 2 N.D. 100 ± 4 85 ± 8 N.D. 
Fbg (%) 100 ± 5 98 ± 3 72 ± 2** 100 ± 10 121 ± 8 70 ± 3** 
Tbil (µmol/L) 8.7 ± 0.7 8.5 ± 0.2 8.4 ± 0.4 8.6 ± 0.3 9.0 ± 0.2 8.6 ± 0.4 
ALT (U/L) <20 <20 <20 <20 <20 <20 
AST (U/L) 43 ± 8 31 ± 4 32 ± 2 34 ± 3 40 ± 4   39 ± 5 




comparable to levels in siNEG animals at five days after injection, despite 




Figure 3. Comparison of gene transcript levels in mouse livers following HNF4α 
knockdown and liver-specific targeted deletion of Hnf4a 
Livers from siHNF4α injected animals (panel A, black bars) and siNEG injected animals as 
controls (panel A, open bars) were subjected to control and coagulation gene transcript 
levels by QPCR. In panel B, coagulation transcript analysis for liver materials from HNF4α-
null mice (KO) or control mice (FLOX) is included for comparison 
25
. Data are presented for 
mice two days post siRNA injection or app. 6 weeks gene ablation (i.e. 6 weeks old HNF4α-
null mice). β-actin was used as internal control for quantification and normalization. The ΔCt 
values of the individual samples were related to the mean ΔCt of the siNEG or FLOX control 
group. Data are expressed as mean with error bars representing the difference between 2 
POWER of upper and lower range of the mean ΔΔCt (see figure 1 legends). Data were 
statistically analysed using Mann Whitney Rank Sum test. P-values < 0.05 were regarded as 
statistically significant. *P<0.05, **P<0.01, ***P<0.001. On the x-axis the coagulation genes 
are ranked according to the magnitude of effects observed in the siRNA injected animals. 








































Changes in liver coagulation gene transcription following HNF4α and 
C/EBPα knockdown  
Livers of siHNF4α injected animals with strong reduction in HNF4α 
transcript and protein levels (two days) displayed markedly and significantly 
reduced transcript levels of Hrg (-97%), Proz (-70%), Serpina5 (-62%), F11 
(-50%), F12 (-46%), F13b (-41%), Serpinf2 (-36%), F5 (-38%), F9 (-27%) 
(Figure 6A). For the other coagulation genes that were analysed (Figure 
3A) we did not observe significant changes as compared to siNEG injected 
animals. At five days, transcript levels of Hrg, Proz, Serpina5, F11 and F12 
(-73%, -24%, -79%, -26%, and -27%, respectively) remained reduced, 
despite the limited level of HNF4α knockdown at this time point (Figure 2A, 
6C). Interestingly, at five days, significant elevations in transcript levels of 
Serpinf2, Serpind1 and Pros1 (+20%, + 22%, +32%, respectively) were 
observed (Figure 6C). Overall, the HNF4α-mediated downregulation of 
coagulation gene transcript levels in livers of siHNF4α injected animals 
seemed to largely reproduce those observed in 6 week old HNF4α-null 
mice with prolonged HNF4α ablation in the liver from birth on (compare 
Figure 3A, 3B), albeit at a lower extent and, importantly, with two-day 
siHNF4α injected animals not showing any upregulating effects. 
Compared to HNF4α, C/EBPα knockdown had a more modest impact on 
coagulation gene transcription. Strong reduction in C/EBPα transcript and 
protein levels resulted in small though significantly reduced transcript levels 
of fibrinogen α and γ (Fga and Fgg -25% and -24%, respectively) and F5 (-
27%) at two days post siC/EBPα injection. Only, the reduction in F5 
transcript levels persisted upon prolonged C/EBPα knockdown (-31%). At 
this time point also F11 transcript levels became significantly reduced (-
21%). For the many other coagulation genes that were analyzed, neither at 
two (Figure 5) nor at five days (data not shown) post siC/EBPα injection, we 







Figure 4. Hepatic transcription of control genes following HNF4α and C/EBPα 
knockdown  
At two (upper panels) and five days (lower panels) post siRNA injection, mouse livers were 
subjected to transcript levels by QPCR for a panel of control genes. Data are presented for 
siHNF4α (panel A and C, black bars) and siCEBPα (panel B and D, hatched bars) with 
siNEG injected animals as controls (panel A, B, C and D, open bars). β-actin was used as 
internal control for quantification and normalization. The ΔCt values of the individual 
samples were related to the mean ΔCt of the siNEG group. Data are expressed as mean 
with error bars representing the difference between 2 POWER of upper and lower range of 
the mean ΔΔCt (see figure 1 legends). Data and were statistically analysed using Mann 
Whitney Rank Sum test. P-values < 0.05 were regarded as statistically significant. *P<0.05, 
***P<0.001.  








































At two days, plasma from siHNF4α and siC/EBPα injected animals had an 
APTT and PT comparable to siNEG injected animals (Table 2). Although 
analyzed for only a limited number of individual coagulation factors, at this 
time point, HNF4α knockdown coincided with a significant reduction in 
plasma F11 activity levels, but not F12 activity levels. C/EBPα knockdown 
coincided with significant reduction of plasma fibrinogen antigen but not F5 
activity levels.  At five days, siHNF4α injected animals displayed a minimal 
but significant shortening of the PT, while that of siC/EBPα injected animals 
was minimally but significantly prolonged. Plasma fibrinogen antigen levels 
remained reduced upon prolonged C/EBPα knockdown. 
 
 
Figure 5. Overview of gene transcript levels in mouse livers following C/EBPα 
knockdown 
Livers from siCEBPα injected animals (hatched bars) and siNEG injected animals as 
controls (open bars) were subjected to control and coagulation gene transcript levels by 
QPCR. Data are presented for mice two days post siRNA injection. β-actin was used as 
internal control for quantification and normalization. The ΔCt values of the individual 
samples were related to the mean ΔCt of the siNEG group. Data are expressed as mean 
with error bars representing the difference between 2 POWER of upper and lower range of 
the mean ΔΔCt (see figure 1 legends). Data were statistically analysed using Mann Whitney 
Rank Sum test. P-values < 0.05 were regarded as statistically significant. *P<0.05, **P<0.01, 
***P<0.001. On the x-axis the coagulation genes are ranked according to the magnitude of 







Figure 6. Hepatic coagulation gene transcription following HNF4α and C/EBPα  
knockdown  
At two (upper panels) and five days (lower panels) post siRNA injection, mouse livers were 
subjected to coagulation gene transcript levels by QPCR. Data are presented for siHNF4α 
(panel A and C, black bars) and siCEBPα (panel B and D, hatched bars) with siNEG injected 
animals as controls (panel A, B, C and D, open bars). β-actin was used as internal control 
for quantification and normalization. The ΔCt values of the individual samples were related 
to the mean ΔCt of the siNEG group. Data are expressed as mean with error bars 
representing the difference between 2 POWER of upper and lower range of the mean ΔΔCt 
(see figure 1 legends). Data were statistically analysed using Mann Whitney Rank Sum test. 
P-values < 0.05 were regarded as statistically significant. *P<0.05, **P<0.01, ***P<0.001. 
Only those coagulation genes are presented for which transcript levels were significantly 
affected by siHNF4α or siC/EBPα (in two or five days study group). On the x-axis the 
coagulation genes are ranked according to the magnitude of effects observed in the two day 
groups. 









































In the present study we used an in vivo synthetic small interfering RNA 
approach to determine in mice the direct role of the liver transcription 
factors hepatocyte nuclear factor 4α (HNF4α) and CCAAT/enhancer-
binding protein α (C/EBPα) in coagulation gene transcription under 
conditions minimizing methodology or target-related secondary effects. 
Shortly (two days) post intravenous siHNF4α injection, we observed 
(strong) reductions in transcript levels of the Hrg, Proz, Serpina5, F11, F12, 
F13b, Serpinf2, F5, and F9 genes indicating that these coagulation genes 
are under direct regulatory control of HNF4α. The relatively modest but fast 
reduction in transcript levels of Fga, Fgg and F5 observed two days post-
siC/EBPα injection indicating that these genes likely targets for direct 
regulatory control by C/EBPα. However, siC/EBPα injection also rapidly 
induced increased C/EBP transcription, indicating a rapid onset of 
C/EBPα-related secondary (compensatory) effects and therefore we cannot 
exclude an underestimation of C/EBPα’s direct role in coagulation gene 
transcription. Overall, we conclude that in the mouse, HNF4α has a direct 
and essential regulatory role for multiple hepatic coagulation genes. For 
C/EBPα, such a role is more restricted, but may be underestimated as 
result of an unexpectedly fast compensatory upregulation of Cebpb 
transcription. 
Analyzing the impact of liver HNF4α deficiency on a genome-wide scale 
using microarrays identified an estimated 20% of the hepatically expressed 
genes affected by HNF4α deficiency to be upregulated.32;34 Scarb1 and 
Cd36 were among the genes that were strongly upregulated in liver-specific 
HNF4α deficient mice while unaffected upon acute siRNA-mediated HNF4α 
knockdown in mice. It was speculated that Scarb1 increase may be a 
secondary consequence of altered lipid homeostasis (e.g., due to changes 




mechanism may account for Cd36 albeit that this gene is predominantly in 
the liver Kupffer cells. The absence of any statistically significant 
upregulating effects regarding transcription in livers of mice two days post 
siHNF4α injection, including Scarb1 and Cd36, suggests that at least a 
large portion of the upregulating effects observed in the liver-specific 
knockouts are secondary to prolonged HNF4α disruption. This supports the 
use of our siRNA approach for in vivo studies on the regulating role of liver 
transcription factors. In this light, it is worthwhile to denote that prolonged 
knockdown i.e. 5 days post siHNF4α, despite a limited efficacy of hepatic 
HNF4α knockdown (Figure 2A and 2D), resulted in likely secondary 
upregulating effects for a number of the coagulation genes (Serpinf2, 
Serpind1, Pros1, Figure 6C). 
In the present study, C/EBPα was selected as the second liver transcription 
factor in this first synthetic siRNA study on transcriptional control of liver 
coagulation genes given the observations from a recent ChIPseq study on 
the genome-wide occupancy of C/EBPα in livers of multiple species.16 In 
this study, fibrinogen A (FGA) and prothrombin (F2) were among the few 
genes (from a total of 32 in mouse genome) that were located near 
ultraconserved C/EBPα binding regions. Indeed, in our mouse study we 
identified Fga as one of the few genes likely to be under direct 
transcriptional control of C/EBPα. 
However, F2 was clearly not affected following siC/EBPα, suggesting that 
the C/EBPα  binding site located 64 bp from the transcription start site in 
the mouse F2 promoter is not critical for physiological control of F2 
transcription. In addition, we were surprised not to find an effect of 
siC/EBPα on mouse hepatic F9 transcription. In humans, carriers of 
hemophilia B Leiden have a causal mutation in a C/EBPα binding site in F9 
promoter,17 and in line, mice with prolonged C/EBPα ablation the liver 
display reduced hepatic expression of F9.18 Possibly, C/EBPα interaction 
with the F9 promoter, and also that of F2, is of high affinity, requiring only 








































limited levels of C/EBPα binding to drive transcription. Despite the strong 
level C/EBPα reduction of transcript (-92% and -87% at 2 and 5 days 
respectively) and protein levels (Figure 2B and 2D) by our synthetic siRNA 
approach this may not be sufficient to unmask a role for C/EBPα for these 
type of targets. Alternatively, the observed unexpectedly rapid upregulation 
of C/EBP transcript following siC/EBPα injection, may functionally replace 
C/EBPα in liver.36 Indeed, C/EBP has been shown to compensate for loss 
of C/EBPα in the regulation of Pck1 gene expression.37 Thus, provided the 
C/EBP transcript rapidly translates to protein (which we did not determine) 
a compensation for loss of C/EBPα by C/EBP cannot be excluded and 
may explain the absence of effects of siC/EBPα on F2 and F9 and possibly 
other genes. 
The in vivo siRNA delivery procedure used had low toxicity without effects 
on circulating liver enzymes tested ((Table 2) as expected28). However, as 
compared to the control siRNA, both siHNF4α and siC/EBPα had a mild 
transient effect on serum alkaline phosphatase levels, the circulating 
marker for biliary obstruction. This suggests the presence of target-related 
(mild) hepatotoxic effects. Alternatively, changing in ALP levels may reflect 
a specific transcriptional regulatory role of HNF4a and C/EBPa for genes 
involved in regulation of bile acid biosynthesis, as has been reported for 
HNF4α 25. In the present study, whether siHNF4α or C/EBPα had an 
immediate effect on bile acid biosynthesis genes like Cyp7a1, Cyp27a1 and 
Cyp8b1 was not investigated. 
Negative control siRNAs - siRNAs with sequences that do not target any 
gene products - are essential to control for the effects of siRNA delivery, 
and to determine whether a siRNA is considered to have a positive, 
negative, or neutral effect in a particular assay. In our animal studies, we 
included a commercially available negative control siRNA that was 




transcript sequences (for description see methods and 29). This negative 
control siRNA incorporates the same chemical modifications and is purified 
to the same rigorous specifications as the target-specific siRNAs (siHNF4α 
and siCEBPα). In addition, this negative control siRNA virtually lacked 
effects on gene transcription as determined for multiple cell lines following 
exposure of relatively high doses of negative control siRNA and analyzed 
by whole genome expression arrays. Despite the careful design of the 
negative control, we cannot exclude that in our experiments the control 
siRNA itself had influence on our genes of interest, and thereby leading to 
misinterpretation of the findings. To fully exclude such misinterpretation, in 
vivo experiments should be expanded with multiple carefully designed 
negative and multiple target specific siRNA. The HNF4α-mediated 
(downregulatory) changes in control and coagulation genes in livers of 
siHNF4α injected animals largely reproduced that of 45-day-old HNF4α-null 
mice and wild-type mouse primary hepatocytes rapidly after siRNA-
mediated HNF4α knockdown, indicating that the single negative control 
siRNA approach used in the present study allowed reliable estimation of 
the (direct) effects of siHNF4α and also that of siC/EBPα. 
In vitro siRNA screening and validation in (primary) mouse hepatocytes 
showed that the siRNAs targeting HNF4α had higher efficacy than those 
targeting C/EBPα (Figure 1). Remarkably, in vivo we observed the opposite 
i.e. the siC/EBPα were more effective than siHNF4α (Figure 2). Both 
HNF4α and C/EBPα displayed normal and stable expression in primary 
mouse liver cells i.e. Ct comparable to fresh livers. This suggests that the 
discrepancy between the in vitro and in vivo findings could not be attributed 
to a rapid decline in HNF4α in vitro and thereby the efficacy of the siHNF4α 
is over estimated. Whether the difference in efficacy is due to differences in 
in vivo siRNA delivery, processing and or stability of the siRNA is unknown. 
However, it emphasizes that the in vitro experiments (as performed) are 
useful for identifying siRNAs with in vivo potential, but are not fully 








































predictive for identifying most effective siRNA for in vivo use. Although, 
these aspects of in vivo siRNA approach should be improved, this study 
demonstrates that synthetic siRNA provides a simple and fast means for 
determining direct transcription factor involvement in vivo under conditions 
minimizing secondary effects. Here, in vivo siRNA-mediated knockdown 
enabled us to establish the direct contribution of HNF4α and C/EBPα to the 
regulation of coagulation gene transcription. 
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The Forkhead Box A1 (FOXA1) protein either activates transcription 
directly, or modulates the activity of other transcription factors, in particular 
nuclear hormone receptors. In breast cancer cell lines, FOXA1 facilitates 
binding of estrogen-bound estrogen receptor α (ERα) to chromatin and 
represents an important determinant of ERα signaling by estrogen. FOXA1 
is also expressed in normal human and mouse liver, an estrogen 
responsive tissue expressing ERα. To investigate the role of FOXA1 on 
estrogen signaling in liver, FOXA1 was silenced in normal mouse livers, 
and ERα- chromatin interaction and ERα-mediated transcription were 
studied both in the absence and presence of an estrogenic stimulus.  
In the absence of endogenous estrogen production (i.e. conditions of 
ovariectomy), silencing of mouse hepatic FOXA1 transcript levels (>60% 
reduction) resulted in altered transcription of 12 out of 19 hepatic genes 
analyzed. ChIP analysis confirmed that stimulation of hepatic ERα by 17β-
ethinylestradiol increased binding (up to 5-fold) of ERα to genomic regions 
of representative estrogen responsive genes such as Shp, Gpx3, Serpinc1, 
Pck1 and F5. This increased binding was close to background level when 
FOXA1 was silenced. This reduction in ERα-chromatin interaction upon 
FOXA1 silencing did not translate into altered hepatic transcription of 
estrogen-responsive genes. We concluded that in the absence of estrogen, 
FOXA1 contributes to regulation of mouse hepatic (coagulation) gene 
transcription. FOXA1 can modulate the estrogen-induced ERα interactions 
with hepatic chromatin. However, despite the modulatory potential at the 
chromatin level, under the present study conditions, lowered hepatic 
FOXA1 levels did not modify the estrogen-induced transcriptional changes 





The FOXA subfamily of winged-helix transcription factors includes 
Forkhead Box protein A1 (FOXA1), A2 (FOXA2) and A3 (FOXA3), which 
are encoded by separate genes.1;2 FOXA factors contain a 100 amino acids 
long DNA-binding domain that is highly conserved (at least 92%) within the 
human and rodents FOXA family.3 The FOXA protein family is critical in a 
variety of processes, both during development and in postnatal life.4-12 
Previous gene ablation studies of FOXA factors in mice have shown that 
FOXA2 and FOXA3 altered transcription of genes encoding proteins 
involved in bile acid and glucose metabolism, respectively.7;11;13 FOXA1 
knockout mice showed postnatal growth retardation with a hypoglycemic 
state although expression of FOXA1 target genes involved in hepatic 
gluconeogenesis remained unchanged.14 Mouse studies claimed that 
FOXA proteins can bind nucleosomes,15;16 and open compact chromatin 
structures, thereby facilitating the binding of other transcription factors.17 In 
vitro studies reported the presence of FOXA1 binding sites near estrogen 
receptor α (ERα) binding sites and requirement of FOXA1 for efficient ERα 
binding to estrogen response elements.18-20 Recent studies have shown 
that in breast cancer cells, but also in other types of cancer cells, FOXA1 
act as a ‘pioneer factor’, and FOXA1 is an important determinant of almost 
all ERα-chromatin interactions and of estrogen-ERα mediated 
transcriptional activity.21 Thus, FOXA1 can modulate gene transcription 
including that regulated by ERα, at least in cancer cells. 
Both, ERα and FOXA1 are expressed in normal human and mouse liver.9;22-
24 Several studies, including our own, demonstrated that for the liver, ERα 
is involved in regulating gene transcription.23;25 Whether FOXA1 has the 
potential to directly modulate hepatic gene transcription, and whether 
FOXA1 can modulate ERα-dependent gene transcription in liver tissue, is 
unknown.  




The aim of this study was to investigate the role and interaction of FOXA1 
with ERα in normal mouse liver. RNA interference was used to silence 
FOXA1 expression in mouse liver, and ERα-chromatin interaction and ERα-
dependent transcription were studied both in the presence and absence of 
an estrogenic stimulus. The genes that were selected for analysis were 
hepatic (expressed in liver) estrogen-responsive genes including genes of 
the blood coagulation pathway and hepatic genes that previously were 
demonstrated to be affected by FOXA proteins.7;23;25-28 The results showed 
that FOXA1 had the ability to alter hepatic gene expression independent of 
estrogen hormone in mouse liver. We also showed that silencing of hepatic 
FOXA1 inhibited 17β-ethinylestradiol (EE)-bound ERα chromatin binding for 
a panel of representative hepatic genes. However, despite the modulatory 
potential of FOXA1 on chromatin binding, FOXA1 silencing did not alter 
estrogen-induced transcriptional changes of a panel of representative 
hepatic genes under the present study conditions.  
 
MATERIALS AND METHODS 
siRNA screening in in vitro 
Pre-designed ON-TARGET Plus siRNAs (synthetic small interfering RNAs) 
for mouse Foxa1 mRNAs (designated as siFoxa1) or control siRNA 
(designated as siScrambled) were purchased from Dharmacon Lafayette, 
CO, USA (#1: J-046238-05, #2: J-046238-06, #3: J-046238-07, and #4: J-
046238-08 or siScrambled, D001810-01). Target sequence of siFoxa1 #1-4 
and siScrambled were 5’-CCA GAC CCG UGC UAA AUA C-3’, 5’-UCU 
AUG AAC UCC AUG AAC A-3’, 5’-CCA CGA AUC UCA GCU GCA U-3’, 
5’-GGA GCC AGC CUA CUA CCA A-3’ and 5’-UGG UUU ACA UGU CGA 
CUA AUU-3’, respectively. The most Effective siRNAs targeting Foxa1 
were selected using mouse (C57Black/6J, Charles River) primary 
hepatocytes 24 hours after transfection with 100 nM as described 




time PCR (QPCR, see below). siRNAs were selected for in vivo studies 
based on maximal reduction of Foxa1 transcript levels as compared to 
control (siScrambled) siRNA.  
 
mRNA knockdown and hormone treatment in vivo 
ON- TARGET Plus Control siScrambled and siFoxa1 #2 (Dharmacon 
Lafayette, CO, USA, catalogue numbers D001810-01 and J-046238-06 
respectively) were complexed with Invivofectamine® 2.0 Reagent 
(Invitrogen, Life technologies Corporation, USA) according to the 
manufacturer’s protocol. Eight weeks old female C57Black/6J mice 
(weighing 17–19 gram), were bilaterally ovariectomized under isoflurane 
anesthesia. After two weeks of recovery, the ovariectomized mice were 
intravenously injected via the tail vein with 200 µl complexed siRNA at a 
dose of 7 mg of siRNA per kg body weight (in total 48 animals, 24 animals 
per siRNA). 
Two days post siRNA injection all mice were subjected to liver biopsy (see 
below), to study the effect of FOXA1 silencing in the absence of an 
estrogenic stimulus. Mice (12 mice per treatment/siRNA) were treated with 
vehicle or 1 µg ethinylestradiol (EE, Sigma Aldrich, Steinheim, Germany) 
per mouse d-1. Vehicle/EE treatment was continued for 3 more days, and 
then mice were sacrificed for blood and liver collection. Blood samples on 
sodium citrate (final concentration 0.32%) were drawn from the inferior 
caval vein. Plasma was obtained by centrifugation and stored at -80°C until 
use. Liver was isolated and was snap-frozen for chromatin 
immunoprecipitation (ChIP), mRNA and protein analyses, and stored at -
80°C until use. 
All mice were housed under a 12-h light/dark cycle, with standard chow diet 
and drinking water provided ad libitum. All experimental procedures were 
approved by the animal welfare committee of the Leiden University.  
Liver biopsy 




For liver biopsy, mice were anaesthetized by isoflurane inhalation, and the 
upper ventral abdomen up to the sternum was shaved. An abdominal skin 
incision (for ~1 cm) caudal from the sternum slightly left of the midline was 
followed by incision of the abdominal muscle (0.5 cm). Using a forceps, the 
anterior edge of the left lobule was located, held, and a specimen (40-50 
mg) was taken using a cauterizer with a stainless steel 0.35 mm diameter 
tip (Fine Science Tools). The site of cauterisation was visually inspected for 
absence of bleeding and the left lobule was repositioned in the abdominal 
cavity. From the liver biopsy, 30-50 mg of tissue that appeared free of 
damage caused by cauterisation was immediately snap-frozen for mRNA 
and protein analyses and stored at -80°C until use. The opening in the 
abdominal cavity was closed by a normal running suture (Silkam 2xDS12 
6/0 0,7 45cm 18” Black Silk, braided coated, non-absorbable) for the 
abdominal musculature and the skin. Post-operative analgesia was 
achieved by a single subcutaneous injection with buprenorphine (0.05 
mg/kg). 
 
RNA isolation and real-time RT-PCR 
Liver (biopsy) samples (20-30 mg) were homogenized in RNAzol (Tel-Test, 
Friendswood, Texas, USA) and RNA isolation and cDNA synthesis was 
performed as previously described.25 Gene-specific quantitative real-time 
PCR (QPCR) primers have been described previously;25;29 with exception of 
those for Foxa1 (forward; 5’-ATG AGA GCA ACG ACT GGA ACA G-3’, 
reverse; 5’-TGC TGA CAG GGA CAG AGG AGT A-3’), Foxa2 (forward; 5’-
CGG GGA CCC CAA GAC ATA CC-3’, reverse; 5’-CCA TGG TGA TGA 
GCG AGA TG-3’), Shp (forward; 5’-CAT GGA AAT GGG CAT CAA TA-3’, 
reverse; 5’-CGT GGC CTT GCT ATC ACT TT-3’) and prekallikrein Klkb1 
(forward; 5’-TGG TCG CCA ATG GGT ACT G 3’, reverse; 5’-ATA TAC 
GCC ACA CAT CTG GAT AGG-3’). QPCR was performed on the ABI 




data were analysed using the accompanying Sequence Detection System 
software (Applied Biosystems, Foster city, CA, USA). The comparative 
threshold cycle method with β-actin as internal control was used for 
quantification and normalization. siScrambled and/or vehicle treated 
animals were set as a reference and the ΔCt values of the individual 
samples were related to the mean ΔCt of the reference group. 
 
Immunoblotting 
Frozen liver material (10-20 mg) was grounded, and lysed in RIPA-lysis 
buffer. Cell lysate (25µg) was denatured, separated on 8-10% Novex® Tri-
Glycine gels (Invitrogen®, Carlsbad, CA, USA) (city country), and 
immunoblotted using a goat polyclonal IgG against human FOXA1 (Ab-
5089, Abcam, Cambridge, USA). ß-actin was detected using rabbit 
polyclonal against human ß-actin (Ab8227, Abcam) and served as protein 
loading control. These antibodies are cross-reactive to mouse FOXA1 and 
ß-actin, respectively. Bound IgG was detected using horseradish 
peroxidase-labeled anti-goat IgG (sc-2020, Santa Cruz Biotechnologies, 
Santa Cruz, USA) or anti-rabbit IgG(172-1019, BioRad, Hercules, CA, 
USA) IgG followed by enhanced chemiluminescence system (Amersham 
Pharmacia Biotech, Amersham, UK) to detect peroxidase activity. 
 
Chromatin immunoprecipitation 
Chromatin was prepared from liver samples as described previously.30 
Briefly, about 0.5cm3 liver tissue obtained five days post siRNA injection 
was fixed in 1% formaldehyde and quenched for 5 minutes with glycine 
(0.125M) at room temperature. After washing twice with PBS, the material 
was dounced and filtered through a 100 μm cell strainer. Cells were lysed 
in Lysis-buffer ‘LB1’ (50mM Hepes [pH 7.5], 14mM NaCl, 1mM EDTA, 10% 
glycerol, 0.5% Nonidet-P40, 0.25% Triton-X-100, protease inhibitor 
[cOmplete, EDTA-free, #11873580001; Roche Diagnostics, Mannheim, 




Germany]) and the nuclei were pelleted by spinning at 2000 × rcf (relative 
centrifugal force) for 5 min at 4 °C. Nuclear pellets were lysed in 2 ml Lysis-
Buffer ‘LB2’ (150mM NaCl, 50mM Tris-HCl, pH 7.5, 5mM EDTA, 0.5% 
Nonidet P-40, 1% Triton X-100, protease inhibitor [cOmplete, EDTA-free, 
#11873580001; Roche Diagnostics, Mannheim, Germany]. Chromatin was 
sheared in an ultrasonic bath (Branson), three times 10 minutes, 15 sec 
on/off cycle with high power at 4oC. Samples were immunoprecipitated with 
2 μg ERα antibody MC-20 (Santa Cruz Biotechnology, Santa Cruz, CA) 
according to a published protocol.31 Unspecific binding of protein to beads 
was measured using 2 µg normal rabbit IgG (Millipore, Billerica, 
Massachusetts, USA) as control. Immunoprecipitated and purified DNA 
was amplified by QPCR genomic primer pairs (designed with Primer3Plus 
software) of Shp, Serpinc1 and Pck1 (Supplementary table 1), Gpx3 and 
F5 (EpiTect ChIP qPCR Assay 200, GPM1029444(+)09A, GPM1028370(-
)17A, respectively, Qiagen, Benelux B.V., Venlo, Netherlands). QPCR was 
performed as mentioned above. The comparative threshold cycle method 
with IgG as internal control was used for quantification and normalization. 
Relative enrichment values were calculated by dividing the ChIP values 
obtained with ERα antibody by the ChIP values obtained with Input. ChIP 
was performed independently on liver samples from three mice per group 
and QPCR was performed in duplicate for each sample.  
 
Plasma analyses 
Thrombin generation was assessed as described.32 Briefly, thrombin 
generation reaction was initiated in 1:6 diluted plasma, triggered with 1 pM 
tissue factor (TF) and measured with calibrated automated thrombogram 
(Thrombinoscope B.V., Maastricht, the Netherlands). Accompanying 
software program enabled the calculation of thrombin activity against the 






Data were analysed with the GraphPad Instat software (La Jolla, CA, USA). 
Statistical differences were evaluated using a Mann-Whitney Rank sum test 
(animal studies; transcript data) or Student’s t-test (hepatocyte and ChIP 
studies). A P-value of <0.05 was considered as statistical significant.  
 
RESULTS 
FOXA1 silencing in absence of an estrogenic stimulus  
To investigate the role of FOXA1 in mouse liver gene transcription (both 
estrogen dependent and independent), we followed an RNA interference 
(RNAi) strategy. Previously, we demonstrated that this allows fast and 
acute silencing of hepatic (control) genes and analysing their function in 
vivo.29 First, an effective FOXA1-specific siRNA was selected by 
transfecting mouse primary hepatocytes with four different FOXA1 specific 
predesigned synthetic siRNAs. As shown in Figure 1A, both siRNA duplex 
#2 and #3 resulted in ~90% reduction of FOXA1 transcript levels compared 
to siScrambled control transfected hepatocytes. siRNA duplex #2 was 
selected for large-scale preparation and complexation with a lipid-based in 
vivo transfection reagent optimized for hepatic delivery. First, the role of 
FOXA1 was investigated in absence of estrogen hormone. To this end, 
female ovariectomized C57Black/6J mice were intravenously injected in the 
tail vein with siFoxa1 or siScrambled (7 mg/kg). The extent of in vivo 
FOXA1 silencing was determined both at 2 at 5 days after siRNA injection, 
using liver biopsy (50 mg) and whole liver material, respectively. 
Two days post-siRNA injection, reduction in Foxa1 transcript levels ranged 
from 49% to 72% of that of control siRNA injected animals (Figure 1B). At 
this time point, FOXA1 protein levels were modestly affected, as analysed 
for mice with relatively strong levels of silencing at the transcript level (> 
57%; Figure 1C). Five days after injection, reduction in Foxa1 transcript 
levels ranged from 44% to 73% of control siRNA injected animals (Figure 




1B).  At this time point, relatively low levels of Foxa1 transcript levels were 
associated with low levels of FOXA1 protein in liver (Figure 1C). Although 
quantitative protein data are lacking, this suggests that at 2 days, Foxa1 
transcript reduction did not yet translate into reduced protein levels, 
probably because of a relatively long half-life of the FOXA1 protein. 
We opted to analyze the expression levels of a panel of hepatic genes that 
either have FOXA binding sites in their enhancer region (e.g. F2) or genes 
are regulated by FOXA targets (e.g. Hnf4a, Klkb1, Pck1 and Proc).7;26-28;33 
As shown in Figure 2A and 2B, FOXA1 silencing (both at two and 5 days 
post siFoxa1) did affect hepatic expression levels of F2, but not of Hnf4a, 
Klkb1, Pck1 and Proc, (Figure 2B). F2 transcript levels showed modest, but 
significant, correlation with level of residual hepatic Foxa1 transcript levels 
(r=0.4436, P=0.0460, n=11).  
Two and five days post- siRNA injection, livers samples were also analyzed 
for a panel of known estrogen-responsive genes.23;25 Hepatic Fiba, Src1 
and Hrg transcript levels remained unaffected by siFoxa1 injection (both at 
two or five days post siRNA injection), while hepatic expression of F2, F5, 
F7, F10, F11, F13b, Serpinc1, Gpx3, Apoa4, Apoc2 and Esr1 were 
significantly altered as compared to control siRNA injected animals (either 
two or five days post siFoxa1 injection); at two days, a reduction in hepatic 
transcript levels of Gpx3 (-37%) and Apoa4 (-22%) was observed, while an 
elevation in hepatic transcript levels of F13b (20%), Esr1 (32%), F11 (35%), 
and Apoc2 (43%) was observed (Figure 2C). At five days, hepatic transcript 
levels of F2 (-20%), F5 (-21%), F7 (-22%), F10 (-39%), F11 (-28%), 
Serpinc1 (-19%) and Apoa4 (-10%) were reduced, while Gpx3 (43%) levels 






Figure 1. Screening and validation of siRNA in in vitro and in vivo. Screening of siRNA 
in mouse primary hepatocytes 24 hours after transfection with 100nM of four FOXA1-
specific (#1-4), or a control siRNA (siScrambled, panel A). FOXA1 transcript levels were 
determined by quantitative real-time PCR (QPCR). On the x-axis the siRNA concentrations 
are indicated. The selected siFoxa1-specific siRNA #2 and a control siScrambled were 
subjected to large-scale preparation in the lipid-based in vivo transfection reagent optimized 
for hepatic delivery and intravenously injected in ovariectomized C57Black/6J mice (7 mg 
siRNA per kg mouse, injection volume 200 µl, 12 animals per siRNA). Two days post siRNA-
injection, liver biopsies were performed for transcript analysis (B). Five days post siRNA-
injection mice (n=12 per siRNA) were sacrificed and livers were subjected to FOXA1 
transcript analysis by QPCR (panel B). β-actin was used as internal control for quantification 
and normalization. The ΔCt values of the individual samples were related to the mean ΔCt of 
the reference group (siScrambled). On the x-axis days post siRNA-injections are indicated. 
Data are expressed as mean with error bars representing the difference between 2 POWER 
of upper and lower range of the mean ΔΔCt (difference 2^ΔΔCt+SEM and 2^ΔΔCt-SEM). 




Individual experiments were performed in triplicate. In vitro and in vivo data were statistically 
analyzed using the Student’s t-test and Mann Whitney Rank Sum test, respectively. P-
values < 0.05 were regarded as statistically significant. *P<0.05, **P<0.01, ***P<0.001. In 
addition, immunoblotting for FOXA1 was performed for liver homogenates that were 
prepared for two selected mice (with most efficient knockdown at the mRNA level) per 
siRNA for both two days and five days post injection (panel C). β-actin was used as loading 
control. The uncropped protein blot is in Supplementary Figure 1. 
 
 
Figure 2. Hepatic gene transcription following FOXA1 knockdown in mouse liver. At 
two (upper panels, A and C) and five days (lower panels, B and D) after siRNA injection, 
mouse livers were subjected to gene transcript analyses by QPCR. Data are presented for 
siFoxa1 (gray bars) with siScrambled injected animals as controls (open bars). β-actin was 
used as internal control for quantification and normalization. The ΔCt values of the individual 
samples were related to the mean ΔCt of the siScrambled group. Data are expressed as 
mean with error bars representing the difference between 2 POWER of upper and lower 
range of the mean ΔΔCt (see figure 1 legends). Data were statistically analyzed using the 
Mann Whitney Rank Sum test. P-values < 0.05 were regarded as statistically significant. 
*P<0.05, **P<0.01, ***P<0.001. On the x-axis the coagulation genes are ranked according to 




Effect of FOXA1 silencing on estrogen-mediated ERα-chromatin binding 
and transcriptional activity 
Two days post-siRNA injection mice were treated with vehicle or 1 µg EE 
per mouse d-1. A dose of 1 µg EE per mouse d-1 was chosen, as this is 
known to result in significant changes in hepatic gene transcription.25 Liver 
samples were collected five days post siRNA injection i.e. after three days 
of daily EE treatment.  
Hepatic transcript levels of Foxa1 were significantly decreased upon EE 
treatment in control siRNA (-36%) as well as in siFoxa1 (-74%) injected 
animals as compared to control siRNA injected animals (Figure 3A). Thus, 
estrogen treatment downregulates hepatic FOXA1 expression in mice, 
adding to the siFoxa1 effects.  
To investigate whether FOXA1 modulates estrogen-induced binding of ERα 
to mouse liver genomic DNA, we performed chromatin immunoprecipitation 
(ChIP) for ERα, followed by QPCR analysis of promoter regions for Shp, 
Gpx3, Serpinc1, Pck1 and F5. These genes are established estrogen 
responsive genes and contain ERα binding motifs.23;25 ERα-ChIP followed 
by real-time PCR was used with primers flanking the promoter regions of 
the selected genes. In animals injected with control siRNA, estrogen 
treatment induced a 2 to 4-fold enrichment at selected promoter regions of 
studied genes (Shp, Gpx3, Serpinc1, Pck1 and F5: Figure 3B). ERα binding 
at promoter regions of studied genes remained unaffected in animals 
injected with FOXA siRNA and vehicle treatment (data not shown). As 
shown in Figure 3B, silencing of hepatic FOXA1 strongly and significantly 
reduced estrogen-induced ERα binding to Shp, Gpx3, Serpinc1, Pck1 and 
F5. Thus, silencing of FOXA1 inhibits estrogen-induced binding of ERα to 
chromatin for all genes selected for this analysis. 
We next assessed the effect of FOXA1 silencing on ERα-mediated hepatic 
gene transcription. In control siRNA injected animals treated with EE, we 
observed significant altered hepatic transcript levels of F7, F2, Serpinc1,  






Figure 3. Binding of ERα to chromatin is influenced by expression levels of FOXA1 in 
mouse liver. Ovariectomized C57Black/6J mice were injected with siScrambled or siFoxa1 
(7 mg siRNA per kg mouse) and two days post siRNA injection mice were treated for three 
days with 1µg EE d
-1
 or vehicle per mouse. (A) FOXA1 hepatic transcript levels were 
analyzed using QPCR (n=12 mice per group). β-actin was used as internal control for 
quantification and normalization. The ΔCt values of the individual samples were related to 
the mean ΔCt of the reference group (siScrambled-V). Data are expressed as mean with 
error bars representing the difference between 2 POWER of upper and lower range of the 
mean ΔΔCt (see figure 1 legends). On the x-axis days post siRNA-injections are indicated. 
(B) ERα chromatin immunoprecipitaion (ChIP) was performed on liver samples followed by 
QPCR of known ERα binding regions. Normal rabbit IgG was used as internal control for 
quantification and normalization. The promoter occupancy was analyzed for three individual 
animals in each group and each sample was assayed in duplicate. Data are presented as 
ERα enrichment relative to Input as mean ± standard error (SD). Transcript and ChIP data 
were statistically analyzed using the Mann Whitney Rank Sum test and Student’s t-test, 
respectively. P-values < 0.05 were regarded as statistically significant. *P<0.05, **P<0.01, 
***P<0.001. 
 
F5, PC, Gpx3 and Apoa4, thereby confirming earlier observations (Figure 
4).25 Pck1 and Hnf4α were not affected by hormone, while Shp hepatic 
transcript levels were too low to allow quantification (Figure 4). Despite, the 
relatively strong effect of FOXA1 silencing on ERα-binding to the genomic 




genes, an effect of FOXA1 silencing on EE-induced transcription was 
absent. Silencing of FOXA1 did not modulate the estrogen induced 
transcription of these genes, nor did it affect the transcription of other 




Figure 4. EE-bound ERα hepatic gene transcription is dependent on FOXA1 
expression. Livers from ovariectomized mice, five days post siRNA and after three days of 
EE/vehicle treatment (as mentioned in the legends of Figure 3) were subjected to transcript 
analysis by performing QPCR (see figure 1 legends). Data are presented for 
siScrambled+Vehicle (Open bars), siScrambled+EE (hatched bars) and siFoxa1+EE (Black 
bars). On the x-axis the coagulation genes are ranked according to the magnitude of effects 
observed in siScrambled+EE group. Data are expressed as mean with error bars 
representing the difference between 2 POWER of upper and lower range of the mean ΔΔCt 
(see figure 1 legends). Data were statistically analyzed using the Mann Whitney Rank Sum 
test. P-values < 0.05 were regarded as statistically significant. *P<0.05, **P<0.01, 
***P<0.001 
 
In addition the impact of FOXA1 silencing on EE-induced transcription (of 
Pck1, Serpinc1, F5 and Gpx3) was analysed for a subset of animals that 
were used for ChIP analysis and displayed a relatively strong level of 
FOXA1 ‘knockdown’ (<80%, n=3). Also in these samples, FOXA1 silencing 
did not modulate the estrogen-induced alterations in transcription (Pck1, 
Serpinc1 and F5: Supplementary figure 2). For Gpx3, hormone–induced 




gene expression was reduced upon FOXA1 silencing, but this did not reach 
statistical significance (Supplementary figure 2).  
 
Thrombin generation assay 
Hormone-induced ERα-dependent changes in hepatic coagulation gene 
transcription lead to estrogen-induced changes in plasma thrombin 
generation.34 We used this global plasma coagulation assay to assess 
whether subtle effects of FOXA1 silencing on (hormone-induced) transcript 
impacted the hemostatic balance. In the absence of hormone, FOXA1 
silencing (5 days post siRNA injection) results in a significant increase in 
plasma thrombin generation (increased peak height (nM FIIa) 43±6 vs 
37±6, p=0.032 and increased endogenous thrombin potential (ETP) 
290±44nM vs 242±17nM, p=0.0049, respectively). Estrogen treatment also 
increased ETP compared to vehicle treated animals (306±14nM vs 
242±17nM P=<0.0001; Supplementary figure 3B) and with decreased 
propagation of thrombin generation, which is in line with the overall 
decrease in liver coagulation gene transcript levels and confirms the earlier 
observations.34 Estrogen-induced effects on thrombin generation were not 
affected by FOXA1 silencing (310±13 vs 306±14; Supplementary figure 
3C). Thus, the absence of a modulatory effect of FOXA1 silencing on 
hormone-induced hepatic coagulation gene transcription, was paralleled by 
absence of an effect of plasma thrombin generation (Figure 4). 
 
DISCUSSION 
In the present study, we examined the role of FOXA1 in mouse hepatic 
gene transcription in the presence and absence of estrogen. We observed 
that in the absence of endogenous estrogen, FOXA1 directly regulated 
mouse hepatic (coagulation) gene transcription. In addition, we found that 
changes in FOXA1 expression impacted the interaction between ERα and 




minimally impacted ERα-dependent hepatic gene transcription. Despite the 
negative findings regarding transcription, we conclude that FOXA1 has the 
ability to modulate estrogen-induced ERα chromatin interaction in normal 
mouse liver, similar to what has been observed for estrogen-responsive 
(human) cancer cell lines. 
Previous studies provided evidence that F2, Hnf4a, Klkb1, Pck1 and Proc 
genes are regulated by FOXA proteins (as determined by in vitro reporter 
and mutagenesis studies or in vivo knockout mouse models).7;26;27;35 Hence 
these genes were used as controls in analyzing the impact of silencing 
hepatic FOXA1.  Remarkably, only F2 was confirmed as being under direct 
transcriptional control of FOXA1, while confirmation was absent for Hnf4a, 
Klkb1, Pck1 and Proc gene. In contrast to the previous studies, our study 
was under conditions of ovariectomy (absence of endogenous estrogen); 
and FOXA1 action on Hnf4a, Klkb1, Pck1 and Proc may involve interaction 
with estrogen bound estrogen receptors. Alternatively, effects of FOXA1 
silencing may have been masked by upregulation of FOXA2, which has 
been documented previously.36-38 We determined hepatic transcript levels 
of FOXA2, which remained unaffected upon FOXA1 silencing 
(Supplementary figure 4). Although this does not exclude that sufficient 
FOXA2 is available or FOXA2 protein levels were affected by FOXA1 
knockdown and underlied the absence of effects of FOXA1 silencing on 
Hnf4a, Klkb1, Pck1 and Proc. Despite the lack of confirmation for the latter 
genes, we report that a number of well-documented hepatic genes were 
responsive to FOXA1, thereby, suggesting that FOXA1 has a role in the 
constitutive expression of hepatic genes, which may extend beyond the 
genes analyzed. Genome- wide transcriptional analysis (RNAseq) may 
provide further insights in the role of FOXA1 in transcriptional control in 
normal liver.  
Decreased ERα-chromatin binding upon hepatic FOXA1 silencing did not 
result in altered estrogen ERα-mediated hepatic gene transcription. So far, 




we have no good explanation for this. Possibly extended estrogen 
exposure masks the role of FOXA1 in ERα-induced hepatic gene 
transcription. Normally, exogenous estrogen acts fast and rapidly (within 
few hours) modulates hepatic gene transcript levels.25 We also examined 
whether FOXA1 silencing resulted in altered estrogen ERα-mediated 
hepatic gene transcription upon a short term estrogen exposure (5 hours 
after estrogen administration). However, FOXA1 silencing was also unable 
to modulate short-term effects of EE (data not shown). Alternatively, EE 
may impact the transcription via ways other than estrogen receptors, 
thereby being out of reach of FOXA1 effects.39 However, previous studies 
demonstrated that the genes analysed are induced by EE via pathways that 
solely rely on estrogen receptor α.25 Furthermore, we cannot exclude that 
exogenous estrogen alters the transcript levels of our genes of interest by 
modulating the stability of transcripts. This may be an ERα dependent 
process that is not regulated at the level of the gene promoter39 and 
thereby insensitive to FOXA1-mediated modulation of ERα-binding to 
promoter regions. We concluded from the present study that FOXA1 
modulate ERα-chromatin binding also in normal livers as it does in (human) 
cancer cell lines. Future studies should focus on the importance of this 
interesting interaction between hepatic FOXA1 and ERα. 
Previous studies have shown that estrogen exposure causes a rapid down-
regulation of the steady-state level of ERα expression, thereby providing a 
negative feedback mechanism to (down) regulate ERα itself and the genes 
regulated by ERα.40;41 Here, we showed that estrogen treatment also 
induced a considerable (30%) down- regulation of hepatic FOXA1 levels 
(Figure 3A and Supplementary figure 1). This opens up the possibility that 
FOXA1 is involved in the negative feedback regulation in ERα signalling. 
Such a role may also be of therapeutic relevance in cancers where 




In summary, our data demonstrated that FOXA1 regulated hepatic 
(coagulation) gene transcription in mouse liver independent of endogenous 
estrogen. FOXA1 silencing interfered with the interaction of ERα-chromatin 
binding, for a panel of representative estrogen-responsive genes but this 
did not translate into altered response of ERα on hepatic transcription. We 
concluded that FOXA1 can facilitate estrogen ERα-chromatin binding in 
normal mouse liver, similar to what observed for estrogen-responsive 
(human) cancer cell lines. 
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Supplementary figure 2. Sub-analysis of EE-bound ERα hepatic gene 
transcription.  
 
Sub-analysis of Figure 4 was performed 
on samples which were used for ChIP 
assay (n=3 for each group). Data are 
presented for iScrambled+Vehicle (Open 
bars), siScrambled+EE (hatched bars) 
and siFoxa1+EE (Black bars). Data are 
expressed as means with error bars 
representing the difference between 2 
POWER of upper and lower range of the mean ΔΔCt (see figure 1 legends). Data were 








Supplementary figure 3. Thrombin generation assay 
 
Thrombin generation were assessed in 1:6 diluted mouse plasma of five days post injection. 
(A) Effect of FOXA1 silencing on thrombin generation, siScrambled control siRNA (solid line) 
and siFoxa1 siRNA (dashed line) (B) Thrombin generation affected upon estrogen hormone 
treatment, siScrambled vehicle (solid line) and siScrambled EE (dashed line) treated 
animals. (C)  In the presence of hormone FOXA1 silencing does not affect thrombin 
generation, siScrambled EE (solid line) and siFoxa1 EE (dashed line) treated animals. Data 
represented are of n=12 mice per group. siScrambled mice group set as a reference. P-
values < 0.05 were regarded as statistically significant. 
 
Supplementary figure 4: Gene expression of hepatic FOXA2 
 
Data are presented for siFoxa1 (gray bars) with 
siScrambled injected animals as controls (open bars). 
β-actin was used as internal control for quantification 
and normalization. The ΔCt values of the individual 
samples were related to the mean ΔCt of the 
siScrambled group. Data are expressed as mean with 
error bars representing the difference between 2 
POWER of upper and lower range of the mean ΔΔCt 
(see figure 1 legends). Data were statistically analyzed 
using Mann Whitney Rank Sum test. P-values < 0.05 







Supplemental table 1: QPCR primer sequences for ChIP 
Gene  Forward primer (5’- 3’) Reverse primer (5’- 3’) 
Shp GGGCATCAATAGAAACAGCAG TGCCCTTTATCGGATGACTC 
Serpinc1 ATCCTTTGGTTGCCCTTACC TAAGCATTGCGCCTTTCC 
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Mice deficient in the anticoagulants antithrombin (Serpinc1) or protein C 
(Proc) display early lethality due to thrombosis-related coagulopathy, 
thereby precluding their use in gene function studies or thrombosis models. 
Here, RNA interference was used to silence Serpinc1 and/or Proc in normal 
adult mice, and the severe coagulopathy following combined ‘knockdown’ 
of these genes is reported. Two days after siRNA injection, (occlusive) 
thrombi were observed in (large and medium-sized) vessels in multiple 
tissues, and hemorrhages were prominent in the ocular, mandibular, and 
maxillary areas. Tissue fibrin deposition and plasma fibrinogen lowering 
accompanied this phenotype. The coagulopathy was prevented by 
dabigatran treatment. Silencing Serpinc1 alone yielded a comparable but 
milder phenotype with later onset. The phenotype was absent when 
targeting Proc alone. We conclude that RNA interference of Serpinc1 
and/or Proc allows studying the function of these genes in vivo, and 






Wild type mice do not spontaneously develop venous thrombosis. Knock-
out mice for the natural anticoagulants antithrombin (Serpinc1) and protein 
C (Proc) feature spontaneous thrombosis-related coagulopathy1;2, and 
succumb during embryogenesis and/or perinatally, precluding their use in 
studies on the function of these anticoagulants, or as a model for 
thrombosis. To overcome early lethality we employed RNA interference to 
silence antithrombin and protein C production, alone or in combination, in 
livers of wild type mice. Here, we report the spontaneous thrombotic 
phenotype observed shortly after this treatment. 
  
METHODS 
Effective synthetic siRNAs (Life Technologies, Carlsbad, USA) targeting 
Serpinc1 and Proc were identified using mouse hepatocytes as described 
previously3. Selected siSerpinc1, siProc (sequences, see supplemental 
methods) and control siNEG (Life Technologies), complexed with 
Invivofectamine® (Life Technologies), were tail vein-injected in 8-10 weeks 
old female C57Black/6J mice (Charles River, Maastricht, The Netherlands), 
alone or in combination. Mice were sacrificed at different time points and 
subjected to necropsy according to international pathology guidelines4. 
Liver Serpinc1 and Proc transcript, plasma antithrombin, protein C, 
thrombin-antithrombin complexes, and fibrinogen levels, PT and aPTT, and 
tissue fibrin deposition were analyzed as described previously3;5;6.  
 
RESULTS AND DISCUSSION 
Intravenous injection of siSerpinc1 or siProc (7 mg siRNA/kg body weight) 
resulted in a strong reduction in Serpinc1 or Proc hepatic transcript 
(4±0.3% and 11±0.5% of siNEG-treated animals, respectively (n=3)) and 
plasma antigen level (1±2.4% and 2±1.8% of siNEG, respectively (n=3)) 
after 2 days. In siSerpinc1-injected mice, plasma thrombin-antithrombin 




complexes were not detectable (<2 ng/ml), indicating that low plasma 
antigen was not due to consumptive loss, at least for antithrombin. At 2 
days the animals appeared fully normal (observation in 6 animals per 
siRNA). A similar reduction in transcript and plasma antigen level was 
observed when animals were treated with a combination of siSerpinc1 and 
siProc (7 mg/siRNA/kg; n=6, Figure 1A, B). However, here, 2 days after 
injection, one animal died and the remaining  5 animals displayed severe 
weight loss (-15.62.4%, P=0.0011 vs siNEG-treated animals (n=6)), 
lethargy, unresponsiveness to stimuli, and hypothermia. Four of the 5 
surviving animals featured unilateral lesions involving the eye 
(exophthalmos), intraocular and periocular hemorrhages (Figure1C). 
Maxillary, mandibular and submandibular regions were severely swollen 
and showed focally extensive subcutaneous and intramuscular 
hemorrhages especially involving the masseter muscle (Figure1D). In 2 
animals hind leg cyanosis was observed (Figure 1G). Because of the 
severe and irreversible clinical conditions animals were promptly sacrificed 
also allowing further pathological and biochemical analyses. In affected 
animals, collecting citrate-blood from the caval vein was difficult or not 
possible, likely because of circulatory failure and shock. At day 3 and 4, the 
surviving siSerpinc1/siProc animal and siSerpinc1-alone animals also 
featured the clinical signs (hind leg cyanosis not observed). During 5 days 
of observation none of the siProc-treated animals (n=6) featured 
abnormalities.  
Because of the severe symptoms in the Serpinc1/siProc group further 
experiments using the 7 mg/siRNA/kg dose were discontinued. Using half 
the dose of Serpinc1/siProc (3.5 mg/siRNA/kg) reproduced most pathology 
findings (n=13), and all animals showed the described clinical signs within 
72 hours after siRNA injection. However, weight loss was less severe (-




were not observed, and appropriate collection of citrate-blood was possible 
for most animals. In total, 19 out of 19 siSerpinc1/siProc (sum of animals 
for 3.5 and 7 mg/kg dose) versus 0 out of 11 siNEG-treated animals 
featured abnormalities (P<0.0001, Fisher’s exact test). 
Necropsy was performed on siSerpinc1/siProc (7 and 3.5 mg/siRNA/kg 
dose, n=5 and 12, respectively) and siSerpinc1 animals (7 mg/siRNA/kg, 
n=6). Sagittal and coronal serial sections of the head showed severe 
multifocal hemorrhages within the eye (Figure 1E), surrounding muscles 
and harderian glands (Figure1E, F). The masseter and temporal muscles of 
affected eyes consistently displayed severe hemorrhages, mild muscle 
degeneration and necrosis. Hemorrhages and vascular thrombi were 
observed in the above-mentioned areas and submucosa of the palate, 
nasal turbinates, tongue and subdural spaces. Lesions were observed in all 
animals and were comparable between the siSerpinc1/siProc and 
siSerpinc1-alone groups. Hind leg cyanosis, if present, coincided with 
hemorrhages and thrombi in the subcutis and tibia-femoral muscular fibers 
(Figure1H). Regarding the liver, in at least six specimens (high and low 
dose of siSerpinc1/siProc) multifocal areas of necrosis were grossly visible 
(Figure 1I). Microscopic abnormalities in the liver were found for all animals 
and ranged from minimal multifocal hepatic degeneration and presence of 
rare thrombi (4 out of 12 animals receiving the low dose of 
siSerpinc1/siProc, 4 out of 6 animals receiving siSerpinc1 alone) to 
multifocal, extensive areas of severe coagulative and lytic necrosis with 
(occlusive) thrombi in large and medium-sized vessels (Figure 1J, for 8 out 
of 12 animals receiving low dose siSerpinc1/siProc, all animals receiving 
high dose siSerpinc1/siProc, 2 out of 6 animals for siSerpinc1-alone). In 
head, leg and liver, thrombi were located in veins, characterized by 
organized fibrin layering, and surrounding tissues devoid of inflammatory 
cells, indicative for an acute process. Neither animal featured lesions, 




thrombi and/or hemorrhages in kidney or gastrointestinal tract. Minor 
incidence was observed in heart, lung, and brain.  
Biochemical analysis of livers of siSerpinc1/siProc-treated animals at 3.5 
mg/siRNA/kg demonstrated fibrin deposition (Figure 1K), coinciding with 
reduced plasma fibrinogen levels (Figure 1L). For the 7 mg/siRNA/kg dose, 
liver fibrin deposition was massive and plasma fibrinogen was virtually 
absent (Figure 1L), indicating a relation with the siRNA dose. Liver fibrin 
deposition was at background level in siNEG (5.42.7 ng/mg, n=11) and 
siProc-treated animals (5.62.7 ng/mg, n=6). Remarkably, siSerpinc1-
treated animals had low liver fibrin deposition (10.73.1 ng/mg, n=6). As 
siSerpinc1 animals displayed a later onset of the phenotype (reproduced in 
additional experiments; both 3.5 and 7 mg/siSerpinc1/kg, n=5 per dose), 
and unaffected plasma fibrinogen (data not shown), this suggests that a 
combination of siSerpinc1 and siProc results in a more severe phenotype 
than the sum of siSerpinc1 and siProc alone. Likely, combined loss of 
Serpinc1 and Proc pushes the animals over a thrombotic threshold that 
cannot be reached with diminution of either one. 
Tissue fibrin deposition was not restricted to the liver; lungs of 
siSerpinc1/siProc-treated mice demonstrated increased fibrin deposition 
(3.5 mg/siRNA/kg dose; 50±38 (n=13) vs 13±7.3 ng/mg (n=11) in siNEG, 
P=0.0010), despite minor incidence of microscopically visible thrombi in this 
tissue (1 animal out of 12). 
The presence of (occlusive) thrombi and fibrin deposition in 
siSerpinc1/siProc-treated animals indicates that the observed coagulopathy 
is thrombotic in nature and hemorrhages are likely secondary to 
consumption of fibrinogen and/or other coagulation factors as illustrated by 
prolonged PT and aPTT for 6 out of 10 siSerpinc1/siProc-treated animals 
(>70 and >120 s, respectively vs 11±0.3 and 27±1.6 s for siNEG-treated 






Figure 1: Phenotypic Appearance of Mice Following Silencing of Hepatic Antithrombin 
and Protein C Production.  A. Effectiveness of silencing of Serpinc1 and Proc in mouse 
liver. siRNAs targeting Serpinc1 and Proc were complexed, mixed and intravenously 
injected in C57Black/6J mice at a dose of 3.5 (hatched bars, n=13) or 7 (black bars, n=6) mg 
per siRNA per kg mouse. At two days post siRNA injection mice were removed from the 




experiment, sacrificed and livers were subjected to Serpinc1 (left) or Proc (right) transcript 
analysis by qPCR. β-actin was used as internal control for quantification and normalization. 
The ΔCt values of the individual samples were related to the mean ΔCt of the reference 
group (siNEG, 7 mg per kg, open bars, n=11); B. Plasma antithrombin (left) and protein C 
levels (right) in siNEG (open circles), siSerpinc1/siProc-injected animals at 3.5 (open 
squares) or 7 (black squares) mg siRNA per kg mouse; C. Right eye of a siSerpinc1/siProc 
injected animal. Unilateral severe exophthalmos and periocular hemorrhages; D. Multifocal 
hemorrhages in the mandibular, submandibular area, and masseter muscle; E. Severe 
multifocal hemorrhages within the eye (HE-stained 5-μm section, magnification 40x); F. Eye 
region: harderian glands with multifocal hemorrhages (h) and thrombus (t) presence (HE-
stained 5-μm section, magnification 100x); G. Cyanosis of the right hind leg; H. 
Hemorrhages (arrow) and thrombi (arrow heads) were present in the subcutis but also 
among muscular fibers of the tibial and femoral areas (HE-stained 5-μm section, 
magnification 200x); I. Liver (formalin-fixed specimen) presenting focally extensive areas of 
necrosis (asterisk); J. Liver section presenting severe multifocal to coalescing coagulative 
necrosis (cn) and thrombosis (t) in hepatic vein (HE-stained 5-μm section, magnification 
100x); K. Liver fibrin, and L. plasma fibrinogen in siNEG (open circles), siSerpinc1/siProc 
injected animals at 3.5 (open squares), or 7 (black squares) mg siRNA per kg mouse; M. 
Treatment of siSerpinc1/siProc-injected treated mice (3.5 mg/kg dose) with dabigatran 
etexilate (DE). DE was administered by oral gavage of 3 mg per mouse at 7 am, 3 and 11 
pm for five days, starting the day before siRNA injection. This results in an aPTT of 66.9±6.8 
(s) to 36.2±4.4 (s) as determined in a parallel treated control group at two hours after dosing 
and one hour before the next dose (vehicle treated animals aPTT of 26.7±5.1 and 24.5±0.8 
(s), respectively). Presence of periocular contusion (arrow heads) for vehicle treated animals 
(left) and not DE-treated animals (right); N. Liver fibrin deposition in siSerpinc1/siProc (3.5 
mg per siRNA per kg) treated with DE (open squares) or vehicle (filled squares). Data were 
analyzed with the Instat software (GraphPad, San Diego, USA). Statistical differences 
between control siNEG and siSerpinc1, siProc, siSerpinc1/siProc were evaluated using a 
Mann-Whitney Rank sum test. P-values<0.05 were regarded as statistically significant. 
*P<0.05, †P<0.01, ‡P<0.001 
 
tion underlied this phenotype, siSerpinc1/siProc-treated mice (3.5 
mg/siRNA/kg) were administered the thrombin inhibitor dabigatran 
etexilate. Dabigatran prevented the clinical signs of siSerpinc1/siProc-




treated siSerpinc1/siProc animals, n=16-17, P=0.0011), exophthalmos and 
periocular contusion (Figure 1M, 0/17 versus 16/ 16, P<0.0001, Fisher 
test), and largely suppressed liver fibrin deposition (Figure 1N). 
We conclude that silencing hepatic Serpinc1/Proc or Serpinc1 alone 
acutely induces thrombotic coagulopathy. This study a) highlights the 
importance of protein C and antithrombin in animals under challenge-free 
conditions, b) points to synergism between these anticoagulant systems c) 
will help to further unravel the in vivo function of these anticoagulants and 
d) provides a novel, controlled model for venous thrombosis research. 
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Structural information on reagents and negative control 
 
We used pre-designed siRNAs for mouse Serpinc1 and Proc mRNAs that 
were  purchased from Life Technologies, Carlsbad, California, USA 
(Ambion Silencer® Select Pre-designed siRNA) catalogue number 
4404014. For mouse Serpinc1 with sense sequence 
UCCUGGUUCUUAUAAGGGATT and antisense sequence 
UCCCUUAUAAGAACCAGGAAG and for mouse Proc with sense 
sequence GCAAGAUCCUCAAACGAGATT and antisense sequence 
UCUCGUUUGAGGAUCUUGCTGT. Ambion's siNEG (catalogue number 
4404020) was used as control siRNA. This negative control siRNA was 
selected using a modified blast to account for short sequence length and 
demonstrated to exclude significant homology to any known gene targets in 
RefSeq and MirBase (more detailed documentation on this negative control 
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Single nucleotide polymorphisms (SNPs) in a 4q35.2 locus that harbors the 
coagulation factor XI (F11), prekallikrein (KLKB1), and a cytochrome P450 
family member (CYP4V2) genes are associated with deep venous 
thrombosis (DVT). These SNPs exert their effect on DVT by modifying the 
circulating levels of FXI. However, SNPs associated with DVT were not 
necessarily all in F11, but also in KLKB1 and CYP4V2. Here, we searched 
for evidence for common regulatory elements within the 4q35.2 locus, 
outside the F11 gene, that might control FXI plasma levels and/or DVT risk. 
To this end, we investigated the regulation of the orthologous mouse gene 
cluster under several metabolic conditions that impact mouse hepatic F11 
transcription. In livers of mice in which HNF4α, a key transcription factor 
controlling F11, was ablated, or reduced by siRNA, a strong decrease in 
hepatic F11 transcript levels was observed that correlated with Cyp4v3 
(mouse orthologue of CYP4V2), but not by Klkb1 levels. Estrogens induced 
hepatic F11 and Cyp4v3, but not Klkb1 transcript levels, whereas thyroid 
hormone strongly induced hepatic F11 transcript levels, and reduced 
Cyp4v3, leaving Klkb1 levels unaffected. Mice fed a high-fat diet also had 
elevated F11 transcription, markedly paralleled by an induction of Klkb1 
and Cyp4v3 expression. We conclude that within the mouse F11, Klkb1, 
Cyp4v3 gene cluster, F11 and Cyp4v3 frequently display striking parallel 













Blood coagulation serine protease factor XI (FXI) contributes to hemostasis 
by activating coagulation factor IX 1. Although bleeding associated with FXI 
deficiency is relatively mild, there has been a resurgence of interest in FXI, 
because candidate gene studies revealed a role of high FXI levels as a risk 
factor for venous thrombosis 2;3. Factor XI, like the blood coagulation 
protease factors II, VII, IX, X, XII and XIIIb, is produced primarily in 
hepatocytes. FXI is a dimeric serine protease that is structurally closely 
related to prekallikrein, a serine protease that is also involved in the intrinsic 
blood coagulation pathway 4. Both factor XI and prekallikrein are activated 
by active coagulation factor XII 5-7.  
The genes encoding FXI (F11) and prekallikrein (KLKB1) are located in 
tandem on the long arm of chromosome 4 (4q35.2) directly downstream 
from the cytochrome P450 family member (CYP4V2) gene and family with 
sequence similarity 149 A (FAM149A, Figure 1). The size of this 4q35.2 
locus is approximately 200 kb (197.715 bp; position 187297059—
187494774). It is assumed that CYP4V2, which has a role in fatty acid 
metabolism 8, is not involved in coagulation. The function of FAM149A is 
unknown. Recent genetic studies of deep vein thrombosis (DVT) reported 
that several common single nucleotide polymorphisms (SNPs) in the F11, 
KLKB1, and CYP4V2 region (not including FAM149A) were associated with 
DVT and plasma FXI antigen levels (individuals with FXI antigen in 90 
percentile having a 2-fold increased risk for DVT) 3. The two SNPs that 
were independently associated with DVT and high plasma FXI antigen 
levels were located within F11 gene (rs2036914 and rs2289252) 9. SNP 
rs13146272 within CYP4V2 was associated with DVT and FXI levels also 
after adjustment for rs2036914 and rs2289252 9. Of note, these three SNPs 
remain associated with DVT after adjustment for FXI levels. Possibly 
average levels are not so much affected by these SNPs, but rather that 
peak levels (e.g. as a result of hormone stimuli) are affected. It could also 



































be that qualitative changes in the FXI protein not detected by quantitative 
effects are responsible (e.g. missense or splice changes). Alternatively, 
SNPs in F11 and CYP4V2 may also affect the expression of KLKB1, which 
is clearly also a strong candidate DVT risk gene. The above suggests that 
the DVT risk associated with variation in the 4q35.2 region may not 
necessarily be solely attributed to F11 gene variation and/or FXI protein 
levels. Furthermore, it opens the possibility that KLKB1 and CYP4V2 may 




Figure 1: F11 gene locus organization in human (A) and mice (B). Vertical bars 
representing exons, and lines representing introns. Arrows show the orientation of 
transcription. Source; http://www.ncbi.nlm.nih.gov/ 
 
Experimental evidence for the possible regulatory interaction of the genes 
within 4q35.2 region should follow from a detailed in vitro analysis of this 
cluster, but is complicated as this requires expression analysis of the entire 
cluster with (the as yet unidentified) regulatory elements in their natural 
positions. Such analysis is limited by the size of the cluster (~100 kb). In 
mice, F11, Klkb1 and Cyp4v3 (the mouse orthologue of CYP4V2) are also 
located together (Figure 1). Furthermore, in mice, hepatic F11 transcription, 











in estrogen status 10, thyroid hormone status [unpublished observation] or 
dietary fat intake 11. Here, we took advantage of mouse hepatic F11 
transcriptional responsiveness to obtain additional evidence for possible 
regulatory interaction of the genes within the 4q35.2 locus. To this end, we 
studied variation in hepatic F11, Klkb1 and Cyp4v3 transcript levels under a 
number of conditions that affect mouse hepatic F11 gene transcription. We 
observed parallel responses in F11 and Cyp4v3 transcript levels when 
hepatocyte nuclear factor 4α (HNF4α), estrogen, and dietary status were 
varied. In contrast, Klkb1 only showed an F11-like response for the fat 
feeding condition.  
 
MATERIALS AND METHODS 
Materials 
Livers from 45-day-old female liver-specific Hnf4a-null mice with a liver-
specific deletion of exons 4 and 5 of the Hnf4a gene (Hnf4a-floxed/floxed 
with albumin-Cre; KO) or control mice (Hnf4a-floxed/floxed without albumin-
Cre; FLOX) were described previously 12. Liver from 10-week-old 
ovariectomized female C57BL/6J mice treated orally with synthetic 
estrogen hormone (17α-ethinylestradiol) (1µg) once for ‘single doses’ or 
daily for 10 days for ‘multiple doses’ and respective vehicle-treated controls 
have been described previously 10.  
 
Animal experiments. 
C57BL/6J males and females were purchased from Charles River 
Laboratories (Maastricht, the Netherlands) and housed under a 12-h 
light/dark cycle, with standard chow diet and drinking water provided ad 
libitum. For studying the impact of the natural estrogen 17ß-estradiol, 8-
week-old female mice were bilaterally ovariectomized under isoflurane 
anesthesia, and after a 2 week recovery period, they were randomly 
assigned to either the experimental group or vehicle treatment group. 17ß-



































estradiol (Sigma Aldrich, Steinheim, Germany) stock was prepared in 
ethanol and diluted in arachid oil at a final concentration of 1% ethanol prior 
to injection. 17ß-estradiol was injected subcutaneously once or for 5 days, 
at a (daily) dose of 2 µg per mouse. For the vehicle treatment, mice were 
subcutaneously injected with 100 µL of arachid oil with an ethanol 
concentration of 1%. 
For study the effect of thyroid hormone, male C57BL/6J mice, 8 weeks of 
age, were fed a low iodine diet (ICN Biomedicals, Inc., Aurora, OH) and 
drinking water supplemented with 1% (wt/vol) potassium perchlorate 
(Sigma). 3,3′,5-triiodo-L-thyronine sodium salt (T3) (Sigma Aldrich) stocks of 
1 mg/ml were prepared in 4 mM sodium hydroxide and stored at 4 degrees 
Celsius. For injection, a T3 stock was diluted to 2.5 µg T3/ml in phosphate 
buffered saline supplemented with 0.02% bovine serum albumin with a final 
concentration of sodium hydroxide of 0.2 mM. Mice received a daily 
intraperitoneal injection of (0.5 µg) 200 µl thyroid hormone solution for 14 
days. 
For studying the effect of fat feeding, 8-week-old male C57BL/6J mice were 
fed a low-fat control diet (LFD; 10% energy in the form of fat, D12450B, 
Research Diet Services, The Netherlands) as a run-in for a period of 2 
weeks. Subsequently, they were randomly assigned to either the 
experimental group fed a high-fat diet (HFD; 45% energy in the form of fat, 
D12451, Research Diet Services, The Netherlands) or maintained on the 
control LFD for 1 or 7 days. 
For small interfering (si) RNA-mediated knockdown of HNF4α in 8-week-old 
female mice, a control siRNA (siNEG; cat. # 4404020, Ambion, Life 
Technologies Corporation, USA) and a siRNA tested in mouse primary 
hepatocytes to be effective to reduce HNF4α transcript and protein levels 
by 90% at a concentration of 3 nM were used as described previously 13. 
The sequences of the two siHNF4α RNA-strands were, sense: 5  -AGA 











GAC CUC UUG-3  (siHNF4α, cat. # 67635). Control siNEG (catalogue 
number 4404020) and siHNF4α were complexed with Invivofectamine® 2.0 
(Invitrogen, Life technologies Corporation, USA) exactly according to the 
manufacturer’s protocol. Subsequently, C57BL/6J mice were intravenously 
injected via the tail vein with 200µl complexed siRNA, a dose of 7 mg of 
siRNA per kg body weight.  
At the indicated time points, 17ß-estradiol-treated, T3-treated, fat-fed, or 
siHNF4α injected animals and the respective controls were anesthetized by 
a subcutaneous injection with a mixture of ketamine (100 mg/kg), xylazine 
(12.5 mg/kg) and atropine (125 μg/kg) after which the abdomen was 
opened by a midline incision and a blood sample on sodium citrate (final 
concentration 0.32%) was drawn from the inferior caval vein. Plasma was 
obtained by centrifugation and stored at -80°C until use 10. Liver was 
isolated and weighed, and part of a liver lobule was snap-frozen for mRNA 
analyses and stored at -80°C until use. All experimental procedures were 
approved by the animal welfare committee of the Leiden University (under 
registration # 10244, 10032 and 11005). 
  
Hepatic transcript and plasma protein analyses 
RNA was isolated from mouse livers and subsequently analyzed for 
transcripts by quantitative real-time PCR as described previously 10. The 
gene-specific quantitative primers used are presented in Table S1. ß-actin 
was used as an internal control for normalization and quantification. The 
ΔCt values of the individual samples were related to the mean ΔCt of the 
reference group (i.e. ΔΔCt). Values are expressed as mean (2 POWER of 
mean ΔΔCt) with a lower range (2 POWER of mean ΔΔCt+SEM) and an 
upper range (2 POWER of mean ΔΔCt-SEM).  
Plasma FXI activity levels were determined as described previously 10. 
Respective control groups were used as a reference.  
 




































Data were analyzed with ‘GraphPad Instant’ software and statistical 
differences were assessed using the Student’s t-test (plasma analysis) or 
the Mann-Whitney Rank sum test (transcript levels). The Pearson 
correlation coefficient (r) was used to evaluate whether hepatic transcript 
levels were correlated. A p-value <0.05 was considered to be significant. 
 
RESULTS 
To find support for the hypothesis of common regulatory elements in the 
4q35.2 locus, we examined whether F11, Klkb1 and Cyp4v3 transcription in 
mice responds in a concerted manner to stimuli affecting F11 transcript 
levels i.e. estrogen hormone 10 and thyroid hormone treatments 
(unpublished observation) and fat feeding 10;11. Before doing so, we first 
investigated the regulatory role of hepatocyte nuclear factor 4α (HNF4α) for 
the genes located in this locus, as this transcription factor controls the F11 
gene 14. In livers of 45-day-old mice lacking HNF4α in liver (KO), the F11 
transcript levels and Cyp4v3 levels were strongly reduced or even absent 
when compared to their control littermates (FLOX) (-96 and -90%, 
respectively; Table 1). For Klkb1, located in between the F11 and Cyp4v3, 
transcript levels were also clearly affected by HNF4α status, but to a lesser 
extent (-48%, Table 1). As these reducing effects may be secondary to 
changes in liver physiology due to prolonged (45 days) ablation of hepatic 
HNF4α, transcript levels of the gene cluster in adult C57BL/6J mice, in 
which hepatic Hnf4a was rapidly reduced by means of a liver-targeted 
specific small interfering (si) RNA were also examined. Two days after 
intravenous injection of a double-stranded siRNA known to be effective for 
Hnf4a knockdown, a 61% reduction of hepatic Hnf4a transcript levels was 
observed that correlated with the reduction in F11 and Cyp4v3 transcript 
levels (-52% and -61% respectively, Table 1). Klkb1 transcript levels were 











F11 and Cyp4v3 transcript levels in the individual mice strongly and 
significantly correlated (Figure 2A; Table 2), whereas F11 and Klkb1 were 
not significantly correlated (Table 2). Furthermore, Hnf4a transcript levels 
significantly correlated with F11 and Cyp4v3, but not with Klkb1 (Figure 
S1). The specificity of the effects of HNF4α modulation (KO or in siRNA-
mediated knockdown) on F11, Cyp4v3 and to a lesser extent Klkb1 
transcription are illustrated by the absence of effects for hepatic transcript 
levels of coagulation factor genes F2, F7, and F10, while that of the 
established HNF4α target F12 was clearly reduced (Table 3). 
Subsequently, the effect of estrogen on transcription in the locus harboring 
F11, Klkb1 and Cyp4v3 was determined. In mice, estrogens have an 
overall downregulatory effect on liver coagulation gene transcription, but 
upregulated F11. Both oral administration of the synthetic estrogen 17α-
ethinylestradiol (EE) for 10 days (1 µg/mouse/day) and subcutaneous 
injection of the natural estrogen 17ß-estradiol (E2) for 5 days (2 
µg/mouse/day) to ovariectomized C57BL/6J mice induced moderate 
reductions of hepatic transcript for coagulation factor genes F2, F7, F10 
and F12 as compared to the respective vehicle control treated animals (-38, 
-45, -48 and -24% for EE and -16, -17, -11 and -15% for E2, respectively, 
Table 3). However, the reduction in F10 and F12 transcript levels under E2 
did not reach statistical significance. Although more subtle, for EE, but not 
for E2, these reducing effects were already apparent at 5 hours after a 
single dose of hormone. As expected 10, the opposite was observed for 
F11, with significant increased hepatic transcript levels upon prolonged 
exposure to both EE and E2 (+59% and +62%, respectively; Table 1). 
These changes were apparent at 5 hours after a single dose of EE (+35%) 
and E2 (+31%) (Table 1). For EE, but not for E2, the transcriptional 
response of Cyp4v3, but not that of Klkb1, largely resembled the response 








































Table 1: Transcript levels of F11, Klkb1 and Cyp4v3 in livers of challenged mice.  
  n              F11            Klkb1          Cyp4v3 
Hepatic HNF4α status    
siNEG mice  6      1  (0.95 - 1.05)      1  (0.95 - 1.05)      1  (0.92 - 1.08) 
siHNF4α mice  6 0.48  (0.45 - 0.52)
†
 0.92  (0.88 - 0.97) 0.39  (0.34 - 0.45)
†
 
FLOX mice 8      1  (0.89 - 1.13)      1  (0.91 - 1.11)      1  (0.94 - 1.06) 
KO mice 8 0.04  (0.04 - 0.05)
‡
 0.52  (0.50 - 0.54)
‡
 0.10  (0.09 - 0.11)
‡
 
     
Estrogen hormone     
Vehicle control 5      1  (0.91 - 1.10)      1  (0.96 - 1.04)      1  (0.95 - 1.05) 
EE (1µg, 5 hours) 5 1.35  (1.29 - 1.42)* 1.20  (1.14 - 1.27)* 1.23  (1.17 - 1.29)* 
Vehicle control 10      1  (0.94 - 1.07)      1  (0.93 - 1.07)      1  (0.93 - 1.08) 
EE (1µg/day, 10days) 10 1.59  (1.49 - 1.69)
‡
 1.10  (1.04 - 1.16) 1.65  (1.59 - 1.72)
‡
 
     
Vehicle control 7      1  (0.95 - 1.05)      1  (0.93 - 1.07)      1  (0.93 - 1.08) 
E2 (2µg/day, 24h) 7 1.31  (1.20 - 1.43)* 1.04  (0.98 - 1.11) 1.09  (1.04 - 1.14) 
Vehicle control 7      1  (0.92 - 1.09)      1  (0.92 - 1.08)      1  (0.94 - 1.07) 
E2 (2µg/day, 5days) 7 1.62  (1.46 - 1.80)
‡
 1.02  (0.97 - 1.08) 1.00  (0.96 - 1.05) 
     
Thyroid hormone     
Vehicle control 13      1  (0.94 - 1.07)      1  (0.97 - 1.03)      1  (0.97 - 1.03) 
T3 (0.5µg/day, 14days) 13 1.18  (1.10 - 1.26)* 0.92  (0.89 - 0.95) 0.55  (0.54 - 0.57)
‡
 
     
Feeding condition     
Low fat control 11      1  (0.89 - 1.13)      1  (0.95 - 1.05)      1  (0.90 - 1.11) 
High fat (1 day) 10 1.70  (1.61 - 1.76)
‡
 1.49  (1.44 - 1.53)
‡
 1.67  (1.60 - 1.76)
†
 
High fat (7 days) 8 1.58  (1.42 - 1.76)
‡
 1.32  (1.25 - 1.38)
†
 1.73  (1.66 - 1.80)
†
 
Data are expressed as 2 POWER of mean ΔΔCt with lower and upper range. β-actin was used as internal control for quantification and 




p<0.001. siNEG/siHNF4α mice; mice injected with control (negative) or HNF4α siRNA respectively, KO/FLOX mice; HNF4α conditional 













Figure 2: Correlation between F11 hepatic transcript levels and Cyp4v3 under 
different metabolic conditions. (A) siRNA-mediated HNF4α (●) depletion or control siRNA 
(○) in mouse liver, (B) 10 days of oral EE (●) or vehicle (○) treatment in ovariectomized mice, 
(C) 14 days of T3 (●) or vehicle treatment (○) and (D) mice fed with high (●) or low (○) fat diet 
for one day. Correlations were determined using Pearson correlation coefficient (r). p-values 
< 0.05 were regarded as statistically significant. 
‡
p < 0.001 
 
found for F11 and Cyp4v3 transcript levels. Although Klkb1 and Cyp4v3 
were not affected by E2, we found significant correlations with F11 at 24 
hours (Figure 2B, Table 2). 
Next, the modulation of the F11, Klkb1 and Cyp4v3 harboring locus by 
thyroid hormone was determined. C57BL/6J mice with suppressed 
endogenous thyroid hormone production were treated with triiodothyroxine 
(T3; 0.5 µg T3 per mouse for 14 days). T3 results in a decrease in most 
hepatic coagulation gene transcript levels, with downregulatory effects of -
35 and -27% observed for F2 and F10 respectively, while F7 levels 
remained unchanged (Table 3). In contrast, F11 and F12 displayed a 
statistically significant increase in transcription (+18 and +24% as 



































compared to vehicle, Tables 1 and 3). These upregulatory effects required 
sustained elevation of T3 as none of the transcripts analyzed demonstrated 
an immediate response at 4 hours after a single injection of T3 (data not 
shown). Increased hepatic F11 transcript levels at 14 days of T3 treatment 
coincided with a 45% decrease in Cyp4v3 transcript levels, while Klkb1 
levels were not significantly affected. Consequently, under changing in T3 
levels, significant correlations between hepatic F11, Klkb1 and Cyp4v3 
transcript levels were not observed (Figure 2C, Table 2).   
 
Table 2: Correlation between transcript levels of F11, Klkb1 and Cyp4v3 in 
livers of challenged mice.  
       F11-Cyp4v3       F11-Klkb1 
     r p-values    r p-values 
Hepatic Hnf4α status     
siNEG/siHNF4α mice  0.860 0.0003 0.307 0.332 
FLOX/KO mice 0.994 < 0.0001 0.886 < 0.0001 
     
Estrogen hormone     
Vehicle/EE (1µg, 5hours) 0.703 0.0233 0.475 0.165 
Vehicle/EE (1µg/day, 10days) 0.666 0.0001 0.277 0.2518 
     
Vehicle/E2 (2µg, 24hours) 0.541 0.0457 0.640 0.014 
Vehicle/E2 (2µg/day, 5days) 0.333 0.2450 0.254 0.4032 
     
Thyroid hormone (T3)     
T3 (0.5µg/day, 14days) -0.320 0.1110 0.281 0.164 
     
Feeding condition     
High fat (1 day) 0.881 < 0.0001 0.716 0.0003 
High fat (7 days) 0.778 < 0.0001 0.546 0.019 
 
Correlation between hepatic F11 transcript levels and Cyp4v3 (F11-Cyp4v3) or Klkb1 (F11-
Klkb1) under different metabolic conditions. Data was statistically analyzed with Pearson 
correlation coefficient (r). p-values < 0.05 were regarded as statistically significant. 
siNEG/siHNF4α mice; mice injected with control (negative) or HNF4α siRNA respectively, 
KO/FLOX mice; HNF4α conditional liver knockout mice and control littermates, respectively, 















 Table 3: Transcript levels of F2, F7, F10 and F12 in livers of challenged mice.  
 
 n           F2           F7           F10           F12 
Hepatic HNF4α status     
siNEG mice  6      1  (0.96 - 1.05)      1  (0.96 - 1.05)      1  (0.97 - 1.04)      1  (0.97 - 1.04) 
siHNF4α mice  6 0.90  (0.88 - 0.93) 1.02  (0.97 - 1.06) 1.04  (0.96 - 1.13) 0.65  (0.58 - 0.72)
†
 
FLOX mice 8      1  (0.93 - 1.08)      1  (0.89 - 1.13)      1  (0.90 - 1.11)      1  (0.92 - 1.09) 
KO mice 8 1.17 (1.11 - 1.22) 0.97  (0.93 - 1.01) 0.84  (0.79 - 0.89) 0.05  (0.04 - 0.06)
‡
 
      
Estrogen hormone      
Vehicle control 5      1  (0.90 - 1.11)      1  (0.96 - 1.05)      1  (0.89 - 1.13)      1  (0.94 - 1.07) 
EE (1µg, 5 hours) 5 0.75  (0.72 - 0.78)* 0.75  (0.72 - 0.77)
‡
 0.75  (0.71 - 0.79) 0.72  (0.67 - 0.78)* 
Vehicle control 10      1  (0.95 - 1.05)      1  (0.89 - 1.13)      1  (0.95 - 1.05)      1  (0.96 - 1.04) 
EE (1µg/day, 10days) 10 0.62  (0.58 - 0.66)
‡
 0.55  (0.53 - 0.56)
‡
 0.52  (0.50 - 0.55)
‡
 0.76  (0.73 - 0.80)
†
 
      
Vehicle control 7      1  (0.95 - 1.06)      1  (0.92 - 1.09)      1  (0.94 - 1.06)      1  (0.93 - 1.08) 
E2 (2µg/day, 24h) 7 1.03 (0.98 - 1.08) 1.08  (1.04 - 1.12) 1.15  (1.07 - 1.23) 1.09  (1.04 - 1.15) 
Vehicle control 7      1  (0.97 - 1.04)      1  (0.96 - 1.04)      1  (0.96 - 1.04)      1  (0.92 - 1.08) 
E2 (2µg/day, 5days) 7 0.84  (0.79 - 0.89)
†
 0.83  (0.79 - 0.88)
†
 0.89  (0.84 - 0.94) 0.85  (0.81 - 0.90) 
      
Thyroid hormone      
Vehicle control 13      1  (0.96 - 1.05)      1  (0.97 - 1.03)      1  (0.95 - 1.05)      1  (0.95 - 1.05) 
T3 (0.5µg/day, 14days) 13 0.65  (0.61 - 0.68)
‡
 0.96  (0.90 - 1.02) 0.73  (0.70 - 0.77)
‡
 1.24  (1.17 - 1.31)
†
 
      
Feeding condition      
Low fat control 12      1  (0.95 - 1.05)      1  (0.96 - 1.04)      1  (0.97 - 1.04)      1  (0.97 - 1.03) 
High fat (1 day) 10 1.17  (1.11 - 1.23)* 1.13  (1.07 - 1.19) 1.11  (1.05 - 1.18) 1.13  (1.08 - 1.19) 
High fat (7 days) 8 1.03  (1.00 - 1.06) 1.00  (0.97 - 1.03) 1.02  (0.99 - 1.04) 1.03  (0.98 - 1.08) 
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Table 3: Data are expressed as 2 POWER of mean ΔΔCt with lower and upper range. β-
actin was used as internal control for quantification and normalization. The ΔCt values of the 
individual samples were related to the mean ΔCt of the reference group. p-values < 0.05 





siNEG/siHNF4α mice; mice injected with control (negative) or HNF4α siRNA respectively, 
KO/FLOX mice; HNF4α conditional liver knockout mice and control littermates, respectively, 




Figure 3: Plasma FXI activity under several metabolic conditions. Plasma FXI activity 
was measured under different metabolic conditions i.e.; siRNA-mediated depletion of HNF4α 
(siHNF4α) / siNEG (control siRNA), ovariectomized mice treated with vehicle / EE for 10 
days or with E2 for 5 days, mice treated with vehicle / T3 for 14 days or mice were fed with 
low (control) / high fat diet for 1 day. Same mice were used for plasma and liver transcript 
analysis. For number of animals ‘n’ see Table 1. Data are represented as percentage of 
reference group ± standard deviation; data were statistically analyzed using the Student’s t-
test. p-values < 0.05 were regarded as statistically significant. *p < 0.05, 
‡
p < 0.001 vs 
reference group. 
 
High fat feeding of mice also affects transcription of F11 11. Thus 
transcription of our genes of interest was assessed in livers of C57BL/6J 
mice that were fed a low-fat diet for 2 weeks (10 kcal% fat; LFD) as a run-in 
followed by a switch to a high-fat diet (45 kcal% fat; HFD) known to induce 




maintained on the LFD control diet. Short exposure to the fat-rich diet (1 or 
7 days) strongly induced F11 transcript levels (+70 and +58% for 1 or 7 
days, respectively), without significantly altering the hepatic transcript levels 
of F2 (except at 1 day HFD), F7, F10 or F12 (Table 3). For both time points, 
increased F11 transcript levels coincided with increased Cyp4v3 and Klkb1 
transcript levels with strong correlations (Figure 2D, Table 2). 
The above study conditions affecting mouse hepatic F11 (Klkb1 and 
Cyp4v3) transcription also affected the mouse FXI protein activity at the 
level of the plasma. This resulted in statistically significant correlations 
between hepatic F11 transcript levels and plasma FXI activity, with the 




In the present study, we searched for evidence for the existence of 
common regulatory elements within a locus that has been linked to deep 
vein thrombosis and harbors F11, KLKB1 and CYP4V2 i.e. the 4q35.2 
locus. The size of this gene cluster hampers in vitro analysis of the 
interaction of the genes within the 4q35.2 region. Therefore as an 
alternative, we used mice to study the regulation of the orthologous genes 
in mice under conditions that modulate transcription of the F11 gene. Upon 
modulating hepatic HNF4α levels, estrogen status, thyroid hormone status 
or dietary fat intake, a significant effect on hepatic F11 transcription was 
observed in a setting where transcription of other coagulation proteases 
was not, or differentially, affected. In contrast, parallel responses in F11 
and Cyp4v3 transcript levels were produced when HNF4α, estrogen, and 
dietary status were varied. Klkb1 showed an F11-like response for the fat 
feeding condition only.  
Thus, we conclude that in mice, hepatic F11 and Cyp4v3 display parallel 
transcriptional responses suggesting the presence of shared regulatory 
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elements. Possible concerted regulation does not include the Klkb1 gene, 
despite the fact that it is located in between these two genes. 
Co-regulation of the transcription of genes in close proximity of one 
another, as the F11 and Cyp4v3 genes, may be the result of two different 
mechanisms that are not mutually exclusive. On one extreme, the genes 
may be under the control of a common enhancer that stimulates 
transcription of those nearby promoters with which it can form productive 
transcription factor complexes. On the other end of the spectrum, co-
regulation may be the result of the presence of binding sites of comparable 
importance and activity for the same transcription factor in the various 
promoters. A combination of both scenarios is also possible. In the case of 
a common enhancer, the genes need to be in close proximity of one 
another, in case of the presence of similar transcription factor binding sites 
in their promoters, their relative position is not necessarily important; the 
genes might have been on different chromosomes and the same effect 
would have been observed. The present mouse study shows that sufficient 
HNF4α levels are crucial to the regulation of F11 and Cyp4v3 (Figure S1, 
Table 1). This suggests that HNF4α, at ~50% levels of normal, is the 
limiting factor in the transcription complexes regulating the expression of 
F11 and Cyp4v3. On the basis of these data, one would predict that HNF4α 
regulatory element(s) are present near the murine promoters and/or 
enhancers of the F11 and Cyp4v3 genes. Indeed, the mouse and human 
F11 loci are predicted to carry multiple functional HNF4α binding sites 15;16. 
Hence, such HNF4α binding sites are candidate for the common regulatory 
sequence within 4q35.2 locus.  
Using Genomatix MatInspector and JASPAR programs, we identified two 
putative HNF4α binding sites in the enhancer (~5kb upstream of the start-
site) and one in the promoter region (located just upstream of the 
transcription start site) of F11 gene. No binding sites for estrogen receptor 




addition, direct comparison of the human and mouse (enhancer and 
promoter) sequences did not show very convincing conservation of the 
putative binding sites. This exemplifies that a reliable identification of 
functional binding sites requires, perhaps unsurprisingly, functional data. 
These were beyond the scope of the present manuscript. 
It was proposed that the human SNPs associated with thrombotic risk may 
modulate FXI expression in response to changing age and hormonal levels 
9. Our mouse data demonstrate that the cluster harboring F11, Klkb1 and 
Cyp4v3 is highly responsive to changes in hormones and metabolism. Of 
note, these changes are much larger than, and in a different direction from 
the alterations in the expression of coagulation genes F2, F9, F10, F12, 
which were included as controls in the analysis. Both single/multiple 
estrogen doses were able to modulate F11 hepatic transcription. Studies 
indicated that there are ERα binding sites near the F11 gene 17 which 
explains immediate transcriptional response of F11. Alternatively, 
prolonged thyroid hormone exposure was required to evoke a clear F11 
transcriptional response. This could be explained by an indirect modulation 
involving an intermediate transcription factor (e.g. HNF4α) additional to 
thyroid hormone receptor. A small number of studies reported that 
estrogens, thyroid hormone and dietary fat may affect hepatic HNF4α 18-20. 
Although hepatic HNF4α transcript and protein levels were not affected 
(both) in the conditions mentioned above (Figure S2), this does not exclude 
that HNF4α transcriptional activity is affected by hormones and diet thereby 
contributing to the observed possible concerted regulation of F11 and 
Cyp4v3. Alternatively, dietary fat can induce acute hepatic stress and 
inflammation 11;21 that involving many transcription factors. FOXA1 is one of 
such transcription factor 22 and ChIP-seq data from the ENCODE 
consortium 23 indicates that there are FOXA1 binding sites near the F11 
gene. Whether stress-related FOXA1 or HNF4α contribute to possible 
concerted regulation in the human 4q35.2 locus has not been studied. 
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It was also suggested that human SNPs in F11 and CYP4V2 may impact 
the expression of KLKB1, and thereby increase risk for DVT 18-20. The 
mouse data do not provide additional support for regulatory interaction 
between F11 and CYP4V2 on one hand and KLKB1 on the other hand, and 
make modulation of DVT risk through impact on KLKB1 by SNPs in F11 
and CYP4V2 less likely. 
The mouse data encouraged us to investigate whether SNP rs2036914, 
rs2289252 and rs13146272 within the 4q35.2 locus are related to 
(common) regulatory sequences for this locus. SNPs rs2036914 and 
rs2289252 are located in introns of the F11 gene and ChIP-seq analysis for 
HNF4α or FOXA1 binding sites, among others, does not provide any 
evidence for transcription factor binding sites in these regions. Also, the 
sequences around the SNPs are not strongly conserved in mammals. 
rs13146272 is a missense mutation in CYP4V2 and this position is 
relatively well conserved in other species and in other CYPs. It might be 
speculated that this SNP alters sensitivity or specificity of CYP4V2 and 
thereby affects plasma lipid levels, as some mutations in CYP4V2 have 
been shown to do 24. Thus, SNP rs2036914, rs2289252 and rs13146272 do 
not seem to be present in regulatory sequences in the 4q35.2 locus. 
However, it should be stressed that for all three SNPs, it is still entirely 
possible that they are merely genetically linked to other causal/functional 
SNPs which do impact regulation of the locus.  
Parallel responses in F11 and Cyp4v3 transcript levels were produced 
when HNF4α and dietary status were varied. Such responses were also 
produced upon variation in estrogen, however minimal or not when using 
17ß-estradiol (E2) (Table 1 and 2). Overall ethinylestradiol (EE) treatment 
had stronger impact on hepatic transcription as compared to 17ß-estradiol 
(compare also the effects of the two compounds on F2, F7, F10 and F12 
transcript levels). In contrast to 17ß-estradiol, ethinylestradiol is orally 




the estrogenic compound as compared to a subcutaneous administration 
(17ß-estradiol). This is in line with our earlier observations using these 
compounds 10. For thyroid hormone F11 and Cyp4v3 transcript levels were 
affected in opposite direction. We have no explanation for these opposite 
effects, but these observations highlight that, although mouse F11 and 
Cyp4v3 may share regulatory elements, the transcription of these two 
genes is clearly not under control of one single shared regulatory region.  
Remarkably, only for the estrogen treatment conditions, changes in F11 
transcript levels did not translate into increased FXI plasma protein levels, 
at least at the level of protein activity (Table 1, Figure 3). This phenomenon 
was observed in multiple experiments 10. Whether estrogen possibly 
induces increased plasma FXI antigen, but not FXI protein activity, or 
whether estrogen increases FXI protein clearance and degradation thereby 
masking the effects on transcription on protein levels, has not been studied. 
Alternatively, estrogen may affect other (unknown) mechanism that 
influence FXI activity such as the post-translational modifications. Thus, 
whether changes in hepatic F11 transcript levels truly were not translated 
into changes in plasma FXI (protein and activity) is at present subject to 
speculation. Although not determined, it would also be interesting to 
determine whether effects on hepatic Cyp4v3 transcription translate to 
effects on hepatic Cyp4v3 protein (activity) level. This would shine a light 
on whether parallel transcriptional responses of F11 and Cyp4v3 extends to 
protein level. 
In conclusion, our mouse data demonstrate that within the mouse F11, 
Klkb1, Cyp4v3 gene cluster, in particular F11 and Cyp4v3, frequently 
display a striking parallel transcriptional response suggesting the presence 
of regulatory elements.  We speculate that, if present, SNPs within the 
human orthologues of these unidentified elements could causally influence 
DVT risk. 
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Figure S1:  Correlation between hepatic Hnf4a and F11 (A), Hnf4a and Klkb1 (B) and Hnf4a 
and Cyp4v3 (C) under siRNA-mediated HNF4α knockdown (●) and control siRNA (○) in 
mouse liver. Data were statistically analyzed with Pearson correlation coefficient (r). p-
values <0.05 were regarded as statistically significant. ‡p < 0.001. 




Figure S2: Hepatic transcript and protein levels of HNF4α under metabolically challenged 
conditions in mice. (A) Hepatic transcript levels were determined by quantitative real-time 
PCR. Data are expressed as mean with error bars representing the difference between 2 
POWER of upper and lower range of the mean ΔΔCt. β-actin was used as internal control 
for quantification and normalization. The ΔCt values of the individual samples were related 
to the mean ΔCt of the reference group. On the x-axis the metabolic conditions are depicted. 
Data were statistically analysed using Mann Whitney Rank Sum Test. P-values less than 
0.05 were regarded as statistically significant. *p<0.05. (B) Immunoblotting for HNF4α was 
performed for liver homogenates that were prepared for three randomly selected mice per 
condition. 15µg total protein lysate was loaded in each lane and HNF4α was detected using 
anti-HNF4α antibody (C-19, sc-6556, Santa Cruz Biotech., Santa Cruz, CA, USA). β-actin 
was used as a protein loading control.  
siNEG/siHNF4α mice; mice injected with control (negative) or HNF4α siRNA 



















Venous thrombosis is a common disease, in which a blood clot (thrombus) 
is formed in a vein, obstructing the blood flow.1;2 Thrombosis is considered 
to be a multifactorial disease in which both genetic and acquired risk factors 
are involved to cause disease.3 Some acquired risk factors of venous 
thrombosis are associated with a hypercoagulable state,4-6 which may be to 
a certain extent dependent on the dysregulation of gene expression in the 
liver, as the liver is the major organ that produces coagulation factors. 
Coagulation gene transcription can be modulated at different levels through 
hepatic transcription factors, co-regulatory or intermediate proteins, 
however, the exact contribution of these modulators to coagulation gene 
transcription is largely unknown.  We aimed to study the mechanisms 
underlying hepatic coagulation gene transcription in vivo in mice to advance 
our understanding of why thrombotic risk coincides with abnormal 
coagulation profiles.  
To investigate the exact contribution of hepatic transcription factors, co-
regulatory or intermediated proteins in hepatic coagulation gene 
transcription, we employed small interfering RNA (siRNA) as a research 
tool to knockdown gene expression in mouse liver. The siRNA approach 
allowed us to efficiently knockdown gene expression with minimal 
methodology- and target-related secondary effects. Thus, we studied i) the 
direct role of transcription factors HNF4α and CEBPα in mouse coagulation 
gene transcription ii) the role of co-regulatory or intermediate protein 
FOXA1 in modulating the impact of nuclear hormone receptor on mouse 
coagulation gene transcription and iii) the role of two anticoagulation genes 
(PC and AT) for which loss of function in mice coincides with embryonic 
lethality.  
Relatively rapid knockdown (i.e. two and five days post siRNA injection) of 
HNF4α and C/EBPα led to altered hepatic (coagulation) gene expression 
levels and indicated that these transcription factors are directly controlling 




FOXA1 is required for estrogen bound estrogen receptor α (ERα)-
chromatin interactions in mouse liver as it is in (human) estrogen 
responsive cancer cells. Furthermore, we developed a novel thrombosis 
mouse model through siRNA-mediated transient depletion of two important 
anticoagulant factors, i.e. antithrombin and protein C, in normal adult 
mouse. The novel model achieved by this strategy is technically fast, 
simple, and easily reproducible.  
In summary, we identified a number of genes that are potentially relevant to 
the etiology of venous thrombotic risk. Overall, the siRNA approach proved 
to be a valuable tool in studying hepatic genes that are suspected to play a 
role in the pathophysiology of venous thrombosis.  
 
Hepatic genes contribute to regulate coagulation factor production  
Three independent approaches point to an important role for HNF4α in the 
regulation of mouse coagulation gene expression (chapter 2 and 3): i) An 
in vitro approach in which HNF4α was silenced in mouse primary 
hepatocytes, ii) a conditional knockout mouse approach in which HNF4α 
was deleted in the liver starting at birth, iii) as well as a novel siRNA 
approach where HNF4α was silenced in livers of adult animals in a 
transient and acute fashion. All three approaches yielded essentially the 
same results i.e. HNF4α is a key gene in the regulation of large panel of 
mouse coagulation genes. We now speculate that HNF4α is also important 
to human coagulation, and that variation in HNF4α levels and activity will 
possibly modulate the risk for coagulation abnormalities such as bleeding 
and (venous) thrombosis. The potential clinical importance of HNF4α with 
respect to coagulation has been demonstrated in the past by our 
department for coagulation factor IX, where disruption of a binding site for 
HNF4α in the factor IX promoter results in hemophilia B Leyden.7;8 The 
clinical importance of HNF4α with respect to other (metabolic) pathways 




association studies demonstrated that single nucleotide polymorphisms at 
the HNF4α locus displayed highly significant associations with HDL 
cholesterol levels,9  type 2 diabetes (T2DM) susceptibility,10;11 maturity-
onset diabetes of the young (MODY) susceptibility,12;13 C-reactive protein 
levels14 and ulcerative colitis susceptibility.15-17 Mutations in the HNF4α 
binding site of the apolipoprotein CII (ApoCII) promoter are associated with 
hyperchylomicronaemia.18 Thus, HNF4α can be of clinical importance for 
diseases related to its target genes. Whether genetic variation in the 
HNF4α gene is important for coagulation and thereby venous thrombotic 
disease is unknown. Therefore, we propose to determine whether single 
nucleotide polymorphisms in the gene encoding HNF4α gene are 
associated with altered hypercoagulability and increased venous thrombotic 
risk in large population-based case-control studies such as the MEGA 
(multiple environmental and genetic assessment of risk factors for venous 
thrombosis) study.  
HNF4α, in general, controls constitutive expression of hepatic genes, but 
evidence is emerging that HNF4α itself also is subject to regulation. In vitro 
studies demonstrated that HNF4α activity is modulated by selective 
occupation of its receptor pocket with fatty acids.19;20 Also changes in 
cellular lipids and monosaccharaides affect HNF4α activity and 
transcriptional activation at least as demonstrated for its target steroid 
hormone binding globulin (SHBG).21 For SHBG, thyroid hormone was also 
shown to increase HNF4α-mediated transcription.22 Dietary saturated 
fats increase HNF4α binding activity on ApoCIII promoter and enhanced 
ApoCIII mRNA levels.23 Moreover, HNF4α can cross-talk with nuclear 
receptors since HNF4α directly binds to a number of nuclear hormone 
receptors including estrogen or thyroid hormone receptor by protein-protein 
interaction.24;25 HNF4α compete to bind at the response elements with a 
number of other nuclear receptors including thyroid receptors and estrogen 




for binding to estrogen response elements has for example been described 
for the estrogen-dependent transcription of the coagulation factor XII 
gene.26 Furthermore, the farnesyl X receptor (FXR), a family member of 
estrogen and thyroid hormone receptors, was able to competitively displace 
HNF4α from the promoters of ApoCIII27 and ApoA.28 Recently, genome-
wide binding studies of FXR and HNF4α showed that about 50% of the 
binding sites of these transcription factors overlap in mouse liver, and FXR 
cooperates with HNF4α to modulate gene expression.29 These studies 
suggest that HNF4α transcriptional activity is subject to modulation by 
metabolic and hormonal pathways with involvement of nuclear hormone 
receptors. In our mouse studies on estrogen, progesterone, pregnancy, 
obesity and thyroid hormone, we repeatedly observed changes in hepatic 
gene transcription of multiple HNF4α coagulation targets5;6;30-32 (chapter 2, 
3 and 4). We speculate that pregnancy, contraceptive pill use, 
hyperthyroidism, and obesity, all conditions that are associated with 
increased risk for venous thrombosis, affect HNF4α and thereby control of 
coagulation targets. Further studies are required to gain insight in the 
contribution of HNF4α under these conditions known to increase the risk of 
venous thrombosis. 
In chapter 4, we have shown that silencing of hepatic FOXA1 had no or 
minimal impact on (estrogen-induced changes in) hepatic coagulation gene 
transcription. Surprisingly, this was in a setting where FOXA1 silencing 
strongly affected estrogen-binding to genomic target DNA, including 
coagulation factors. Although we were unable to provide an explanation for 
this discrepancy, this study demonstrated that FOXA1, like in a panel of 
hormone-responsive cancer cells,33;34 is able to modulate estrogen receptor 
DNA-interaction also in normal liver tissue (chapter 4). Recently, genetic 
studies identified mutations within the FOXA1 gene (locus), and mutations 
in the FOXA1 binding sites were associated with increased risk of 




use is associated with a hypercoagulable and prothrombotic state which 
likely originates from the activation of hepatic estrogen receptors, we 
propose, as for hormone-related cancers, to study whether genetic 
variation(s) in FOXA1 contributes to hormone-related venous thrombosis. 
Apart from HNF4α, C/EBPα and FOXA1, we also investigated a fourth 
gene which may modulate hepatic gene coagulation transcription i.e. 
steroid receptor co-activator 1 (SRC1). This factor modulates the activity of 
a panel of nuclear receptors relevant to coagulation gene transcription i.e. 
estrogen receptor, thyroid receptor, and HNF4α.39-43 Following siRNA-
mediated silencing in mouse liver (70% reduction in transcript levels) no 
alterations in coagulation gene transcription were observed, nor did SRC1 
silencing affect coagulation gene transcription induced by estrogens (own 
unpublished observation).  Whether this implies that SRC1 is not important 
for blood coagulation gene transcription, or that compensatory mechanisms 
by related proteins SRC2 or SRC3 mask a potential role of SRC1, is not 
known. In general, the number of the genes investigated here possesses 
related or redundant genes that may provide compensation upon silencing. 
For example, it has been described that SRC2 partially compensates for 
SRC1 function.44 It has been claimed that FOXA1 and FOXA2 have 
overlapping functions and compensate for each other in the development of 
multiple organs.45-48 In chapter 3 we observed C/EBPβ upregulation upon 
silencing of C/EBPα. FOXA1 silencing may have been compensated by the 
action of FOXA2 and/or FOXA3 in our studies, and this has to be evaluated 
further. For future studies of transcription factors and their modulators, we 
propose to include silencing of the gene of interest alone or in combination 
with silencing the genes that may provide a potential backup mechanism. 
Such studies may yield better insight in the role of the individual factors. 
Moreover, combined silencing is a feasible strategy as we demonstrated for 




Besides transcription factors, their co-regulators and their pioneering 
factors, coagulation gene transcription may also be affected by genetic 
factors that modulate the availability of the substrates that activate 
transcription factors. Genetic variation in glucuronosyltransferase-2B7 
(UGT2B7),49 cytochrome P450 3A5 (CYP3A5)50 and nuclear factor 
erythroid-derived 2-like 2 (NFE2L2)51 showed association with an increased 
risk of venous thrombosis. These metabolic enzymes are thought to be 
(directly or indirectly) involved in modulating the inactivation and thereby 
circulating levels of biologically active estrogen. Silencing UGT2B7, 
CYP3A5 and NFE2L2 in livers of mice, using the siRNA strategy used 
throughout this dissertation, may help to further delineate the role of these 
genes in modulating the estrogen activation status and thereby their 
contribution to prothrombotic states in particular under exposure to 
estrogen. Furthermore, it may also aid to understand the contribution of 
these genes to many other diseases in which estrogens are thought to play 
a positive or negative role, such as arterial disease, osteoporosis, breast 
and endometrial cancer.  
 
siRNA based thrombosis mouse model 
Mice do not spontaneously develop venous thrombosis and, consequently, 
an ideal thrombosis mouse model does not exist because thrombosis 
always has to be induced by experimental means. A number of 
experimental models have been developed that rely on vessel wall damage 
due to photochemical injury,52 mechanical trauma,53;54 by applying an 
electric current55;56 or ferric chloride.57-59 In addition, models are available in 
which surgically induced stasis triggers thrombus formation.60 Although 
these models may be helpful to study therapeutic strategies, by nature, 
they have limited value in studying the initiation of ‘spontaneous’ venous 
thrombosis. In addition to these experimental models, several genetic 




carry a prothrombotic state, such as Factor V Leiden (hemizygous) mice, 
thrombomodulin (TM) proline (substitution of Glu 387 with Pro: pro/pro) 
mutant mice,61;62 mice deficient for anticoagulant protein C, protein S or 
antithrombin.63-66  Protein S serves as cofactor for activated protein C. 
Activated protein C degrades factor Va and factor VIIIa, while 
antithrombin inhibits the active site of serine proteases such as 
thrombin and factor Xa (Figure 1). The level of thrombosis varies from 
subtle microvascular thrombosis characterized by development of mild 
fibrin deposition in different tissues (Factor V Leiden and TMpro/pro mice) 
to a severe thrombotic coagulopathy resulting embryonic or perinatal 
lethality (anticoagulant deficient mice). We attempted to develop a novel 
type of spontaneous thrombosis model based on reducing anticoagulation 
by means of siRNA (chapter 5). The spontaneous thrombosis observed 
following knockdown of antithrombin and protein C provides a technically 
simple, fast to perform, and easily reproducible model. However, at present 
the phenotype was always severe and it may be worthwhile to further 
improve this model especially with respect to tuning the degree of severity. 
We have observed that severity of the thrombotic phenotype was siRNA 
and/or dose dependent (chapter 5). A lower dose of antithrombin and 
protein C specific siRNA, and also when excluding protein C siRNA, 
produced a less severe thrombotic phenotype. Thus, we believe that the 
thrombotic phenotype can be further adjusted to a less severe and more 
easily modifiable phenotype. More studies are required regarding the 
initiation, dynamics and histology of thrombosis in this model, and to what 
extent these resemble thrombosis in humans. Recently, it has been 
demonstrated that platelets, neutrophils, and monocytes play an important 
role in the initiation of venous thrombosis in a damage-free model,          
based on flow restriction.67 In addition, neutrophil extracellular traps (NETs) 




in this mouse model.67To what extent inflammatory cells, NETs and FXII 
also contribute to initiation and propagation in our siRNA-based thrombosis 
mouse model needs to be evaluated. Studies in prothrombotic mouse 
models (Factor V Leiden and TMpro/pro) demonstrated that exposure to 
human VT risk conditions (estrogen, obesity, thyroid hormone, and 
pregnancy) did not translate into a more manifest thrombotic phenotype 
(increased fibrin deposition, large vessel thrombosis).31;68;69 Whether 
estrogen, obesity or pregnancy exacerbates the thrombotic phenotype 
induced by siRNA-induced inhibition of antithrombin and protein C is one of 
the issues to be addressed. More knowledge on the mechanisms involved 
and on the responsiveness to challenges will make clear whether the novel 
model forms a good alternative to existing venous thrombosis models, 
which will be of value to further investigating the pathophysiology of venous 
thrombosis, and contribute to the development of novel (bleeding-free) 
strategies for treatment and prevention of (recurrent) thrombosis. 
 
 
Figure 1: Anticoagulation by Protein C/Protein S and antithrombin pathway.  Adapted 




Synthetic siRNA as a tool to study gene function  
Gene inactivation in mice via homologous recombination in mouse ES cells 
is the classical approach for exploring gene function70;71 and has proven to 
be highly valuable in biomedical research.72 Despite its value, this approach 
has also a number of limitations. Many ‘knockout’ mutations are embryonic 
lethal because of the vital role of the gene in development63-66;73;74, thus 
precluding the analysis of the function of the gene in adult mice. In addition, 
full gene deletion may induce adaptative responses, which complicates 
functional analyses and potential masking of the primary role of the gene. 
Mice conditionally lacking the gene of interest i.e. in an inducible and/or 
tissue specific fashion may result in circumvention of embryonic lethality. 
Though, absence of an acute induction of deficiency may still induce 
adaptational response which masks primary gene function. Finally, 
production of these gene targeted mice (both conventional knockout and 
conditional mice) remains an extremely labor intensive and highly 
expensive procedure. 
In the present dissertation, we demonstrated that RNA interference 
mediated by synthetic small interfering RNAs (siRNA) may provide an 
alternative to the gene targeting approach when studying gene function at 
the level of the liver, more specifically the hepatocyte. This siRNA-mediated 
gene knockdown demonstrated to be an effective strategy allowing 
transient but selective and robust knockdown of genes of interest in livers 
of adult mice, without any genomic manipulations.75-79 Depending on the 
target gene, an acute and almost complete hepatic knockdown can be 
provided for a short period of time. The acute knockdown (within 2 days) 
strongly increases the possibility to detect primary gene function, while 
knockdown lasts sufficiently long to allow also monitoring of the induction of 
mechanisms compensating gene knockdown. Although one should be 
aware that in some cases such adaptations are very rapid followed by the 




observed for C/EBPα that acute knockdown was rapidly followed by 
C/EBPβ upregulation (chapter 3). Thus, caution should be taken and 
siRNA may not be the ‘holy grail’ for studying hepatic gene function in 
absence of adaptation. In addition, the siRNA approach does not allow 
studies on the impact of long-term absence of the gene of interest (more 
than one week). Multiple siRNA injections may overcome this limitation.80 
Advantages of siRNA-mediated knockdown over the targeted knockout 
may further include the possibilities of studying gene dosage effects (by 
lowering the siRNA dose)81 and the relative ease to knockdown multiple 
hepatic genes in one single siRNA administration (chapter 5). On the other 
hand, the siRNA approach also has disadvantages that are inherent to 
siRNA use. Although highly specific, off-target effects i.e. the unintended 
suppression of non-target genes, cannot be excluded and may hamper 
analysis of gene function.82;83 Modification of nucleotides in siRNA, lower 
doses of siRNA, and advances in bioinformatics for designing of siRNAs 
may lead to reduction in off-target effects.84-86 Furthermore, exogenous 
siRNA may compete for endogenous and critical RNAi components such as 
RNA induced silencing complex (RISC), thereby, altering the regulatory 
functions of some endogenous cellular microRNAs.87 This may also hamper 
the analysis the function of the target gene. Competition of siRNA with 
cellular microRNAs for RISC may be overcome by using lower doses of 
siRNA. 
We demonstrated in chapter 3, 4 and 5 that lipid-based complexation of 
siRNAs allows efficient delivery of the siRNA to the hepatocyte. This 
approach is preferred when studying genes that are mainly active in this 
cell type such as coagulation genes, apoplipoprotein genes, drug 
detoxification genes, and genes involved in complement etc. However, 
studying genes that are expressed in other liver cell types i.e. Kupffer and 
endothelial cells cannot be investigated with the siRNA delivery vehicle 




In general, many tissues and cell types other than liver/hepatocytes are 
difficult to target by siRNA. It has been demonstrated that use of dedicated 
chemicals may provide delivery of siRNA to organs other than the liver. For 
example, heart and kidney can be targeted by complexing siRNA with 
polyethylenimine (In vivo-jet PEI®), and when injected in the mouse jugular 
or tail vein this allows siRNA delivery to heart and kidney, respectively.88;89 
Furthermore, siRNA delivery to macrophages/microglial cells has been 
achieved through siRNA coupled to a cell specific targeting peptide. siRNA 
was coupled to rabies virus glycoprotein (RVG)-9dR peptide to target α7 
subunit of the acetylcholine receptor (AchR) expressed by 
macrophages/microglial cells.90 siRNA delivery to monocytes was achieved 
with nanoparticles encapsulated with fluorescent labelled siRNA. The 
nanoparticles were formed in a spontaneous vesicle procedure using C12-
200 lipid, disteroylphosphatidyl choline, cholesterol, PEG-DMG and 
siRNA.91 Systemic treatment with nanoparticles-encapsulated with siRNA 
resulted in reduction of target gene (monocytic chemokine receptor, CCR2) 
expression in monocytes.91  
As is evident from the above, so far, a siRNA approach is suitable when 
addressing hepatic gene function in vivo. Future technological 
improvements enabling delivery of siRNA to other organs and cell types, in 
absence of off-target effects, and without interference of regulatory 
microRNA pathways, will increase the application of RNA interference in 
the analysis of gene function. Ultimately, these improvements may also 
open the possibility of therapeutic gene silencing. 
 
siRNA based clinical therapy in near future 
In this dissertation we have demonstrated that hepatic gene expression can 
be reduced in mouse liver using RNAi. The liver is an important organ 
responsible for many vital functions e.g. metabolism of lipids and 




production and detoxification.92-95 Many diseases originate in the liver; 
including fatty liver, cirrhosis, cancer, hepatitis (viral infection), 
hypercholesterolemia, amyloidosis and hemophilia.96-101 Moreover, several 
siRNA lipid-based vehicles are documented to target hepatic genes in 
rodents and non-human primates.102;103 Therefore, siRNA-mediated 
targeting of hepatic genes may provide the first proof of concept for siRNA 
as a therapeutic strategy in general. siRNA-specificity, safety, increased 
circulation time, biodistribution, effectiveness, ease of production and 
manufacturing are important consideration for siRNA therapeutics. 
Moreover, siRNA as therapeutic drug should be patient friendly 
administrated. Although advancements in bioengineering and 
nanotechnology have already led to improved control of delivery and 
release of the siRNA but further developments are required to optimize 
siRNA technology as therapeutic. In this respect, a number of interesting 
clinical trials are going on. 
Tekmira Pharmaceuticals corporation developed a stable nucleic acid lipid 
particle (SNALP) formulation as siRNA delivery vehicle. SNALP-siRNA 
formulations effectively silence gene(s) in several rodents and non-human 
primates.102-104 SNALP formulated ApoB siRNA (TKM-ApoB) is in clinical 
trial for the treatment of hypercholesterolemia by targeting ApoB gene. This 
trial was terminated, as one of the patient (out of 23) with high doses 
experienced potential immune stimulation.105 In September 2010, Tekmira 
Pharmaceuticals started another Phase I trial for the siRNA drug TKM-PKL1 
based on SNALP lipid nanoparticles for patients with solid tumors by 
targeting polo-like kinase 1 (PKL1).106 This phase trial I showed that four 
out of nine dosed patients have achieved clinical benefit. A phase II clinical 
trial will be held in 2014.107  
Alnylam Pharmaceuticals started a phase I trial with another siRNA 
therapy, (ALN-TTR01), for the treatment of transthyretin-mediated 




patients.108 Development of improved and potent ALN-TTR02 is in 
progress. Another dual siRNA therapeutic (ALN-VSP02) is in Phase I 
clinical trial for the treatment of liver cancer and metastatic disease of liver. 
ALN-VSP02 is composed of two separate siRNAs specifically targeting 
mRNA of vascular endothelial growth factor (VEGF) and kinesin spindle 
protein (KSP) mRNA. There are about 20 siRNA therapeutics targeting 
different genes such as RRM2, PKN3, BCR-ABL and PKN3 in ongoing 
Phase I clinical trials.  
Hemophilia is hereditary genetic disorder with deficiencies of procoagulant 
factor VIII or factor IX, impairing hemostatic balance.109;110 There is no cure 
for hemophilia, but a replacement therapy with regular infusion of deficient 
clotting factor is effective.111;112 More recently, Alnylam Pharmaceuticals is 
developing siRNA therapeutics for the treatment of hemophilia and 
bleeding disorders by a hemostatic rebalancing approach i.e. knockdown of 
an anticoagulant factor (antithrombin). Alnylam Pharmaceuticals showed 
that potent and durable knockdown of antithrombin via ALN-AT3 resulted in 
normalized thrombin generation and improved hemostasis in hemophilia 
models.113 However, a clinical trial has still to be started. Our data support 
this hemostatic rebalancing approach as we have shown that siRNA-
mediated transient and strong knockdown of hepatic antithrombin is able to 
shift the coagulation balance and induces thrombosis in mouse (chapter 
5). However, overdosage of antithrombin siRNA may have great impact on 
hemophilia patients; strong knockdown of antithrombin in wild type mouse 
tilted the hemostatic balance towards thrombosis (chapter 5). Therefore, 
siRNA doses and extend of antithrombin knockdown should be carefully 
monitored. 
These clinical trials hold promise for the development of therapeutic gene 
silencing. Successful siRNA mediated knockdown has been demonstrated 
for liver of rodents and non-human primates. A number of clinical trials are 




trials targeting liver genes is an important test case for implication of siRNA 
based therapeutics. In this dissertation we have shown that RNAi is an 
efficient method to study gene function in liver, however, the question 
remains open, “Whether utility of siRNA-based drugs will become a reality 
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Over the past years epidemiological studies have revealed a number of 
acquired risk factors - including estrogen and thyroid hormones, obesity, 
immobility, pregnancy, malignancies, surgery and metabolic syndrome - 
that increase the risk of venous thrombosis. Several of these acquired risk 
factors coincide with changes in the plasma coagulation profile and lead to 
a hypercoagulable state. Since the liver is the major organ for the 
production of coagulation factors, this hypercoagulable state may occur 
when altered transcription of coagulation genes in the liver leads to an 
imbalance in the ratio of pro- and anti-coagulant proteins in the plasma.  
Mechanisms by which acquired risk factors modulate transcription of 
coagulation genes and lead to the hypercoagulable state are not 
completely elucidated. Therefore, we aimed to study the mechanisms 
underlying alterations in hepatic coagulation gene transcription in more 
detail in an attempt to increase our understanding of why a thrombotic risk 
condition coincides with abnormal coagulation profiles. RNA interference 
(via synthetic small interfering RNA; siRNA) was used as a tool to study 
genes involved in coagulation and coagulation control in mice. 
General background on venous thrombosis, risk factors and the possible 
mechanisms by which these factors increased the risk of venous 
thrombosis are discussed in chapter 1. Alterations in coagulation profile by 
thrombotic risk factors occur probably by modulation of gene transcription 
in the liver. Gene transcription can be modulated at several levels, ranging 
from transcription factors, hormone-mediated nuclear hormone receptors, 
co-regulators or intermediate factors. Furthermore, to study the 
mechanisms underlying alterations in hepatic coagulation gene 
transcription, several experimental models and methodologies are 
reviewed. Mice and siRNA-induced gene silencing are discussed as a 





As part of chapter 2, we investigated the contribution of hepatocyte nuclear 
factor 4α (HNF4α) to controlling hepatic transcription of anticoagulant and 
fibrinolytic factors in vitro and in vivo. To study the contribution of HNF4α, a 
dual approach was used; conditional liver-specific Hnf4α-null mouse (in 
vivo) and siRNA-mediated fast and acute silencing of HNF4α in mouse 
primary hepatocytes (in vitro). This latter approach was used to exclude 
delayed/indirect effects of HNF4α deletion (in Hnf4α-null mouse) on 
transcript levels of anticoagulant and fibrinolytic factors. We showed that 
HNF4α is critical in regulating hepatic transcription of anticoagulant and 
fibrinolytic factors in vivo and in vitro. 
In Chapter 3 we established the use of siRNA-mediated gene silencing in 
vivo. Efficient, fast, acute and strong knockdown of transcription factors 
HNF4α and C/EBPα was achieved with sequence specific synthetic siRNA 
in mouse liver. Hepatic gene expression levels of a number of 
procoagulant, anticoagulant and fibrinolytic factors were affected upon 
acute and fast knockdown of HNF4α and C/EBPα in mouse liver, which 
demonstrated a direct role of these factors (HNF4α and C/EBPα) in 
controlling hepatic gene transcription. Moreover, this study showed that 
synthetic siRNA forms a powerful and relatively simple tool to determine the 
role of hepatic transcription factors involvement in vivo. 
Estrogen hormones are able to modulate gene expression of coagulation 
factors via estrogen receptor α (ERα). Moreover, a factor like forkhead 
protein (FOXA1), an intermediate protein which acts as a pioneer factor, is 
a major determinant of estrogen-ERα function in breast and non-breast 
cancer cells, whereas knowledge of the function of hepatic FOXA1 and 
interaction with hepatic ERα is missing. In Chapter 4 we investigated the 
role of FOXA1 in absence of estrogen and as an intermediate factor in 
estrogen response in mouse liver. siRNA-mediated knockdown of FOXA1 
in mouse liver was associated with altered coagulation gene expression in 





coagulation gene transcription. Additionally, we showed that hepatic 
FOXA1 is required for estrogen-bound-ERα chromatin binding in mouse 
liver, as it is in (human) estrogen responsive cancer cells. 
Deletion of anticoagulant factors (antithrombin and protein C) is embryonic 
lethal in mice therefore precluding the use of these knockout mice in gene 
function studies or as thrombosis model. siRNA-mediated gene silencing 
provided a relatively simple tool to study the function of such proteins in 
adult mice, which is described in chapter 5. Combined gene silencing of 
both of these factors resulted in thrombosis-related severe coagulopathy in 
adult mice, showing the vital anticoagulant function of these proteins in 
adult mouse. Moreover, silencing of antithrombin and protein C provided a 
relatively easy, controlled, and novel mouse thrombosis model. 
Single nucleotide polymorphism (SNP) studies demonstrated the 
association of the human chromosome 4q35.2 locus with increased risk for 
deep venous thrombosis. In chapter 6, the aim was to search for 
experimental evidence for putative common regulatory elements in the 
orthologous mouse gene cluster of the human 4q35.2 locus that contains 
the coagulation factor XI (F11), prekallikrein (Klkb1) and cytochrome P450 
family member (Cyp4v3) genes. We analyzed transcript levels of F11, 
Klkb1 and Cyp4v3 in several metabolically challenged mice in which 
hepatic F11 transcript levels were impacted. Metabolic conditions included 
HNF4α deletion, (natural and synthetic) estrogen hormone treatment, 
thyroid hormone, and high fat diet in mice. We observed parallel hepatic 
transcriptional response of F11 and Klkb1 for high fat feeding condition. In 
contrast, strikingly parallel hepatic transcript response of F11 and Cyp4v3 
were observed in all studied conditions except for thyroid hormone 
suggesting the presence of shared regulatory elements.  
In chapter 7, findings presented in this dissertation and possibilities for 




In summary, we utilized a siRNA strategy throughout this dissertation, 
which proved to be a valuable tool to study genes in mice that are 
suspected to play a role in the pathophysiology of venous thrombosis. We 
showed that transcription factors like HNF4α, C/EBPα and FOXA1 (directly) 
regulated the expression levels of a number of hepatic coagulation genes. 
We suggest that these transcription factors are potentially relevant for the 
etiology of venous thrombosis. Depletion of antithrombin and protein C 
leads to the formation of thrombi and fibrin deposition, showing the 
importance of these factors in adult mouse hemostasis and provided a 
novel mouse model featuring a spontaneous (venous) thrombotic 
phenotype. Studies described in this dissertation may contribute to a better 
understanding of which genes are involved in coagulation (control) and how 





Summary in Dutch - Nederlandse samenvatting 
 
In de afgelopen jaren hebben verschillende epidemiologische studies 
aangetoond dat een aantal verworven factoren, waaronder anticonceptiepil 
gebruik (oestrogeen hormoon), schildklierhormonen, obesitas, immobiliteit, 
zwangerschap, (bepaalde) tumoren, chirurgie en metabool syndroom, het 
risico op veneuze trombose verhogen. Sommige verworven risicofactoren 
gaan samen met veranderingen in het plasma stollingsprofiel en leiden tot 
een protrombotische verschuiving van de hemostase balans 
(hypercoagulatie). Omdat de lever van groot belang is voor de aanmaak 
van plasma stollingsfactoren kan de verstoring van deze balans o.a. een 
gevolg zijn van veranderingen in transcriptie regulatie van stollingsgenen in 
de lever. Afwijkende transcriptie van stollingsgenen kan gevolgen hebben 
voor de balans van pro- en antistolling eiwitten in het plasma. Echter, 
mechanismen waarbij verworven risicofactoren de gentranscriptie van 
stollingsfactoren zodanig beïnvloeden dat een protrombotische 
verschuiving van de hemostase balans ontstaat zijn niet volledig bekend. 
Daarom was het doel van het onderzoek om een gedetailleerde studie te 
verrichten naar veranderingen in de gentranscriptie van stollingsfactoren in 
de lever van muizen. Door de moleculaire mechanismen die ten grondslag 
liggen aan transciptionele regulatie van stollingsfactorgenen beter in kaart 
te brengen verschaffen we meer inzicht in de samenhang tussen 
trombotische risicocondities en abnormale bloedstollingsprofielen. We 
hebben voornamelijk gebruik gemaakt van RNA-interferentie (m.b.v. 
synthetische korte interfererende RNA, siRNA) technieken om genen te 
bestuderen die betrokken zijn bij transcriptie regulatie van bloedstolling 
factoren in de muis.  
Achtergrondinformatie over veneuze trombose, risicofactoren en de 
mogelijke mechanismen waardoor deze factoren het risico op veneuze 




moduleren van gentranscriptie in de lever, kunnen trombotische 
risicofactoren mogelijk veranderingen in het coagulatieprofiel veroorzaken. 
Deze gentranscriptie kan op verschillende niveaus gemoduleerd worden, 
variërend van transcriptie factoren, hormoon-gerelateerde nucleaire 
hormoon receptoren, co-regulatoren of intermediaire factoren. Bovendien 
worden een aantal experimentele modellen en methodieken bediscussieerd 
die gebruikt kunnen worden om de onderliggende mechanismen van 
transcriptionele veranderingen van stollingsgenen in de lever te 
bestuderen. Muizen en siRNA-geïnduceerde reductie (knockdown) van 
genexpressie worden besproken als een mogelijke geschikte 
modelsysteem en aanpak voor de studies beschreven in dit proefschrift. 
Als onderdeel van hoofdstuk 2 onderzochten we de bijdrage van 
hepatocyte nuclear factor 4α (HNF4α) in de lever op de transcriptionele 
regulatie van antistollings- en fibrinolytische factoren in vitro en in vivo. Er 
werd een tweeledige aanpak gebruikt om de bijdrage van HNF4α te 
bestuderen: gebruik van conditionele lever-specifieke Hnf4α-null muizen (in 
vivo) en door siRNA-gemedieerde snelle en acute knockdown van HNF4α 
expressie in primaire hepatocyten van muizen (in vitro). Deze laatste 
benadering is gebruikt om latere/indirecte effecten van HNF4α deletie (in 
Hnf4α-null muizen) op transcriptie niveaus van antistollings- en 
fibrinolytische factoren uit te sluiten. We hebben aangetoond dat HNF4α 
essentieel is in de lever voor de transcriptionele regulatie van antistollings- 
en fibrinolytische factoren in vivo en in vitro. 
In hoofdstuk 3 hebben we siRNA-gemedieerde in vivo knockdown 
toegepast om de expressie van specifieke genen te reduceren. Efficiënte, 
snelle, acute en sterke knockdown van twee verschillende 
transcriptiefactoren HNF4α en C/EBPα in muizenlever werd bereikt met 
sequentie-specifieke synthetische siRNA. Genexpressie niveaus van een 
aantal pro-stolling, antistolling en fibrinolytische factoren werden beïnvloed 





aanduid op een directe rol van deze eiwitten (HNF4α en C/EBPα) in de 
transcriptionele regulatie van lever genen. Bovendien toonde deze studie 
aan dat synthetische siRNA een krachtige en relatief eenvoudig hulpmiddel 
is om de rol van lever transcriptiefactoren in vivo te bepalen.  
Oestrogeen hormonen zijn in staat om de genexpressie van 
stollingsfactoren te moduleren via oestrogeenreceptor α (ERα). Bovendien 
is er een factor zoals het forkhead eiwit (FOXA1), een intermediair eiwit dat 
functioneert als een pionier factor, FOXA1 heeft een belangrijk rol in 
hormoongevoelige borstkankercellen. De kennis rondom de functie van de 
lever FOXA1 en interactie van FOXA1 met ERα in lever ontbreekt. In 
hoofdstuk 4 onderzochten wij de rol van FOXA1 bij afwezigheid van 
oestrogeen en als intermediair factor in oestrogeenresponse in 
muizenlever. siRNA-gemedieerde knockdown van FOXA1 in muizenlever 
werd geassocieerd met een veranderde expressie van stollingsgenen in de 
afwezigheid van oestrogeen. Hieruit concluderen wij ten eerste dat FOXA1 
een sleutelrol vervult in de regulatie van transcriptie van 
bloedstollingsgenen. Daarnaast toonden we aan dat hepatische FOXA1 
nodig is voor oestrogeen-ERα gebonden chromatine binding in 
muizenlever, zoals in (humane) oestrogeen reagerende kankercellen. 
Volledige deletie oftewel ‘knockout muizen’ voor genen betrokken bij de 
natuurlijke antistolling (zoals antitrombine en proteïne C) zijn niet 
levensvatbaar en daarom is dit een belangrijk obstakel voor het gebruik van 
deze methode in gen-functie studies of als diermodel voor trombose 
studies. Echter, siRNA-gemedieerde knockdown van gen expressie 
verstrekt een relatief eenvoudig hulpmiddel om de functie van dergelijke 
eiwitten bij volwassen muizen te bestuderen, dit wordt beschreven in 
hoofdstuk 5. Gecombineerd knockdown van beide factoren leidt tot 
trombose gerelateerde ernstige coagulopathie bij volwassen muizen 
hetgeen de vitale anti-coagulerende werking van deze eiwitten bij 




en proteïne C genexpressie verstrekt een relatief eenvoudige, 
gecontroleerde en nieuwe muis trombose model. 
Single nucleotide polymorfisme ( SNP ) studies hebben een verband 
aangetoond tussen de menselijke 4q35.2 gen gebied met een verhoogd 
risico op diepe veneuze trombose. In hoofdstuk 6 was het doel om te 
zoeken naar het experimentele bewijs voor de mogelijk gemeenschappelijk 
regulerende elementen in de orthologe muizen gen cluster van de 
menselijke 4q35.2 regio. Dit cluster  bestaat uit stollingsfactor XI (F11), 
prekallikreïne (Klkb1) en cytochroom P450 familielid (Cyp4v3) genen. We 
hebben het transcript niveaus van F11, Klkb1 en Cyp4v3 geanalyseerd in 
diverse muizen met een afwijking in het metabolisme waarin F11 
transcriptie niveaus werden beïnvloed in lever. De geteste metabole 
defecten zijn HNF4α deletie, oestrogeen (natuurlijke en synthetische) 
hormoon, schildklierhormoon en een hoog vet dieet in muizen. De 
transcriptie van F11 en Klkb1 veranderde op een gelijke wijze wanneer de 
muizen een vetrijk dieet gevoerd werden. Daarentegen transcriptie van F11 
en Cyp4v3 veranderde op aanzienlijke gelijke wijze in lever in alle 
onderzochte studie condities behalve in het schildklierhormoon; dit 
suggereert de aanwezigheid van gedeelde regulerende elementen. 
In hoofdstuk 7 worden de bevindingen in dit proefschrift nader 
bediscussieerd en mogelijkheden voor toekomstig onderzoek besproken op 
basis van de beschikbare recente literatuur. 
Samenvattend hebben we in dit proefschrift gebruik gemaakt van de siRNA 
strategie en dat bleek een waardevolle techniek om de functie van genen te 
bestuderen die vermoedelijk een rol spelen in de pathofysiologie van 
veneuze trombose. We hebben aangetoond dat transcriptie factoren zoals 
HNF4α, C/EBPα en FOXA1 (rechtstreeks) de expressie van een aantal 
lever stollingsgenen reguleren. We stellen dat deze transcriptie factoren 
potentieel relevant zijn voor de etiologie van veneuze trombose. Reductie 





trombi- en fibrinedepositie in weefsels, wat  ten eerste het belang van deze 
factoren laten zien in hemostase bij volwassen muizen. Ten tweede het 
verstrekt een nieuw muismodel die een spontane (veneuze) trombotische 
fenotype aantoont. Studies beschreven in dit proefschrift dragen bij aan 
een beter begrip van de rol van genen bij de bloedstolling (controle) en hoe 
risicofactoren van trombose leiden tot een protrombotische verschuiving 
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